

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Modified minimally invasive surgical technique plus Bio Oss Collagen® for regenerative therapy of isolated interdental intrabony defect: study protocol for a randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-040046
Article Type:	Protocol
Date Submitted by the Author:	04-May-2020
Complete List of Authors:	Zhang, Churen; Peking University School of Stomatology, Zhang, Haidong; Peking University School of Stomatology, Department of Periodontology Yue, Zhaoguo; Peking University School of Stomatology, Department of Periodontology Miao, Lili; Peking University School of Stomatology, Department of Periodontology Han, Ye; Peking University School of Stomatology, Department of Periodontology Liu, Kaining; Peking University School of Stomatology, Department of Periodontology Hou, Jianxia; Peking University School of Stomatology, Department of Periodontology
Keywords:	ORAL & MAXILLOFACIAL SURGERY, PLASTIC & RECONSTRUCTIVE SURGERY, Oral & maxillofacial surgery < SURGERY, Clinical trials < THERAPEUTICS

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Modified minimally invasive surgical technique plus Bio Oss**  
4 **Collagen® for regenerative therapy of isolated interdental**  
5 **intrabony defect: study protocol for a randomized controlled trial**  
6  
7  
8  
9

10  
11  
12 the corresponding author: Dr. Kai-Ning Liu and Dr. Jian-Xia Hou

13  
14  
15 Address: 22 Zhongguancun South Avenue, Haidian District, Beijing 100081, People's  
16  
17  
18 Republic of China.

19  
20  
21 Email address: [liukainingbjmu@163.com](mailto:liukainingbjmu@163.com) and [jxhou@163.com](mailto:jxhou@163.com)  
22  
23

24  
25  
26 Chu-Ren Zhang<sup>1</sup>, Hai-Dong Zhang<sup>1</sup>, Zhao-Guo Yue<sup>1</sup>, Li-Li Miao<sup>1</sup>, Ye Han<sup>1</sup>, Kai-Ning Liu<sup>1</sup>  
27  
28 and Jian-Xia Hou<sup>1</sup>  
29

30  
31  
32  
33  
34 <sup>1</sup>Department of Periodontology, Peking University School and Hospital of Stomatology and  
35  
36 National Engineering Laboratory for Digital and Material Technology of Stomatology and  
37  
38 Beijing Key Laboratory of Digital Stomatology, 22 Zhongguancun South Avenue, Haidian  
39  
40 District, Beijing 100081, People's Republic of China.  
41  
42  
43

44  
45  
46 the total number of words (except abstract, references, tables and figures): 2287.  
47

## 48 **Abstract**

### 49 **Introduction**

50  
51  
52  
53  
54 Periodontal regeneration surgery has been widely used to deal with intrabony defects.  
55  
56  
57 Modified minimally invasive surgical technique (M-MIST) is designed to deal with the  
58  
59 isolated interdental intrabony defects, which has achieved satisfactory periodontal  
60

1  
2 regenerative effect. Bio Oss Collagen® as a bioactive material has been applied to periodontal  
3  
4 regeneration, and it is similar to human cancellous bone, with the ability to promote bone  
5  
6 formation, meanwhile it has very good plasticity and spatial stability. The combination of  
7  
8 different materials and techniques has become a research hotspot in recent years. By  
9  
10 combining the superiority of regeneration technology and materials, better regeneration effect  
11  
12 can be achieved. This study is planned to search the difference between M-MIST plus Bio  
13  
14 Oss Collagen® and M-MIST only in regeneration therapy of intrabony defects.  
15  
16  
17  
18  
19

20  
21 **Methods and Analysis:** The present research is designed as a two group parallel  
22  
23 randomized controlled trial. The needed number of participants is 40. The patients will be  
24  
25 randomly assigned into two groups for further periodontal regenerative surgery. Test group:  
26  
27 M-MIST plus Bio Oss Collagen®. Control group: M-MIST only. After 12 months follow up,  
28  
29 the measurement indexes will be recorded, which include clinical attachment gain,  
30  
31 radiographic intrabony defect depth change, as the primary results, and secondary outcomes  
32  
33 are full mouth plaque scores, probing depth, full mouth bleeding scores, gingival recession,  
34  
35 mobility, height of the gingival papilla, and visual analog scale. The paired samples t test will  
36  
37 be applied to detect any difference between baseline and 1 year registrations. A general linear  
38  
39 model will be performed to study the relationship between the second outcome and primary  
40  
41 outcome.  
42  
43  
44  
45  
46  
47  
48

49 **Ethics and Dissemination:** The present research has gotten approval from the Ethics  
50  
51 Committee of Peking University School and Hospital of Stomatology  
52  
53 (PKUSSIRB-202053002). Data of the present research will be registered in the International  
54  
55 Clinical Trials Registry Platform. Additionally, we will disseminate the results through  
56  
57 scientific dental journals.  
58  
59  
60

1  
2  
3 **Trial registration number:** ChiCTR-2000030851.  
4  
5

6 **Protocol version:** Protocol Version 3, 05.03.2020.  
7  
8

9 **Strengths and limitations of this study:**  
10

11 The present trial will be the first research to compare the periodontal regenerative effect of  
12 M-MIST plus Bio Oss Collagen® and M-MIST only in isolated interdental intrabony defects.  
13  
14

15 The research may provide another therapeutic choice for intrabony defects.  
16  
17

18 This trial is a randomised, examiner-blind clinical trial with long time follow-up.  
19  
20

21 The participants may withdraw during the 1 year follow-up.  
22  
23

24 **Key words:** Intrabony defect, periodontal regenerative therapy, Bio Oss Collagen®,  
25 modified minimally invasive surgical technique.  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 **INTROCDUTION**  
36

37 Periodontal diseases are inflammatory diseases with high incidence around teeth leading to  
38 loss of periodontal attachment and alveolar bone, even to tooth loss.<sup>1,2</sup> It is reported that  
39 periodontitis was one of the most universal diseases around the world.<sup>3</sup> Scaling and root  
40 planning is the essential therapy for every patient.<sup>4</sup> However, for tooth with deep periodontal  
41 pockets, it could not achieve more therapeutic effect than surgical therapy does.<sup>5</sup> After  
42 periodontal initial therapy, the residual deep pockets were often associated with intrabony  
43 defects, which could be identified as a clinical challenge.<sup>6</sup> The intrabony defects may result in  
44 unmanageable inflammation, and even to ultimately tooth loss.<sup>7</sup> Therefore, intrabony defects  
45 are generally regarded as surgical indications.<sup>8</sup>  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Periodontal regeneration surgery has been widely applied to dealing with intrabony defects

1  
2 with the purpose of reformation of periodontal attachment to save the involved teeth  
3  
4 better.<sup>9-12</sup> In the past 20 years, the development of periodontal regeneration therapy is mainly  
5  
6 reflected in two aspects. Firstly, surgical design and techniques have been paid attention to,  
7  
8 especially the minimally invasive surgery techniques.<sup>13-18</sup> Secondly, great progress has been  
9  
10 made in regenerative materials, such as enamel matrix derivative (EMD),<sup>16</sup> demineralized  
11  
12 freeze-dried bone allograft (DFDBA),<sup>17</sup> recombinant human platelet-derived growth factor  
13  
14 BB (rhPDGF-BB),<sup>18</sup> Bio Oss Collagen<sup>®</sup>.<sup>19</sup> These methods had more advantages than simple  
15  
16 flap debridement in increasing clinical attachment and decreasing probing depth of the  
17  
18 affected teeth.<sup>20,21</sup> However, common complications, such as the exposure of barrier  
19  
20 membrane and embedded material, contributed to the poor clinical results of periodontal  
21  
22 regeneration surgery.<sup>22</sup>

23  
24  
25  
26  
27  
28  
29  
30  
31 To solve this problem, many periodontal surgical designs and techniques have been  
32  
33 proposed and continually improved.<sup>23-26</sup> As early as in 1995, Harrel and Ress<sup>23</sup> suggested  
34  
35 applying minimally invasive surgery to periodontal surgical treatment, whose key points were  
36  
37 small incision, small flap, and reduction of damage of soft and hard tissues. In 1995 and  
38  
39 1999, Cortellini and Tonetti<sup>24,25</sup> put forward the papilla preservation techniques, which  
40  
41 preserved the interdental soft tissues as completely as possible, and isolated the operative area  
42  
43 from the oral environment. On this basis, in order to further improve the surgical effect, the  
44  
45 concept of minimally invasive surgery had been proposed and improved gradually. In 2007,  
46  
47 Cortellini and Tonetti<sup>26</sup> proposed a minimally invasive surgical technique (MIST) to deal  
48  
49 with periodontal intrabony defects for more periodontal tissue regeneration. This technique  
50  
51 was designed to reduce the surgical trauma, the operative time, and the postoperative  
52  
53 discomfort.<sup>26</sup> A number of clinical studies<sup>14,27</sup> confirmed its effectiveness and advantages. In  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 2009, Cortellini and Tonetti<sup>15</sup> further designed a modified minimally invasive surgical  
4  
5 technique (M-MIST). This method only opened the buccal tiny flap to ensure adequate blood  
6  
7 supply, tighter primary wound closure and lower risk of bacterial infection.  
8  
9

10 The combination of different materials and techniques has become a research hotspot in  
11  
12 recent years.<sup>28</sup> By combining the advantages of regeneration technology and materials, better  
13  
14 regeneration results can be achieved.<sup>29</sup> M-MIST only opens a small flap in the buccal side to  
15  
16 get a minimal interdental passage, saving the palatal soft tissue.<sup>15</sup> Bio Oss Collagen® is  
17  
18 similar to human cancellous bone, with the ability to promote bone formation.<sup>30</sup> Bio Oss  
19  
20 Collagen® with very good plasticity and spatial stability,<sup>31</sup> is suitable for the small field of  
21  
22 vision resulted by M-MIST. Therefore, the present study is planned to research the  
23  
24 therapeutic effect of M-MIST plus Bio Oss Collagen® and M-MIST only in the periodontal  
25  
26 tissue regeneration of isolated interdental intrabony defects. The presumption was raised that  
27  
28 the combination of M-MIST and Bio Oss Collagen® would lead to a better result in the  
29  
30 periodontal regeneration effect of intrabony defects than M-MIST alone. The practicability,  
31  
32 applicability and extensibility of the combination will be investigated in the present study.  
33  
34 The primary outcomes were clinical attachment gain and radiographic bone filling intrabony  
35  
36 defect, which would be recorded by clinical examination and periapical radiographs. The  
37  
38 clinical attachment gain and bone filling represent the periodontal tissue regeneration.<sup>15</sup> The  
39  
40 secondary outcomes were probing depth, full mouth plaque scores, full mouth bleeding  
41  
42 scores, gingival recession, mobility, height of the gingival papilla, and visual analog scale.  
43  
44 These indexes represent the inflammatory situation of periodontal tissue.<sup>26</sup> The present article  
45  
46 described the design of the trial.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## METHODS AND ANALYSIS

This research is a randomized controlled trial with two parallel groups. It will be carried out on the basis of the World Medical Association Declaration of Helsinki. Patients who are involved in stage III or IV periodontitis,<sup>32</sup> and need periodontal regenerative treatment for isolated intrabony defects are the potential participants. The experimentation of this research will be conducted at Peking University School and Hospital of Stomatology (Beijing, China). The present research has gotten approval from the Ethics Committee of Peking University School and Hospital of Stomatology (PKUSSIRB-202053002) and registered in the International Clinical Trials Registry Platform under the ID: ChiCTR-2000030851. The research framework is showed in Figure 1.

### Participants selection

All participants come from the Periodontology Department, Peking University School and Hospital of Stomatology. At re-evaluation after periodontal initial therapy, if the subject is found to have isolated intrabony defects, he or she will be informed about the study. The potential subjects will receive information about the research plan to get a thorough understanding. The subjects will be incorporated into this trial only after their signature of the consent form. The personal information of the participants will be confidentially stored in our department.

As regard to the patients levels, the following criteria should be met: (1) Age 18 to 75 years; (2) Patients with stage III or IV periodontitis at least 2 months after periodontal initial

1  
2 therapy; (3) Good compliance; (4) Good oral hygiene; (5) The full mouth plaque score and  
3  
4 full mouth bleeding score are both less than 30%. As for the morphological requirements of  
5  
6 the intrabony defect, it should be isolated intrabony defect with more than 3mm depth,  
7  
8 combined with more than 5mm probing depth and attachment loss. In addition, the intrabony  
9  
10 defect should not exceed the lingual surface of root. The morphology of the intrabony defect  
11  
12 will be detected during the operation and finally determined whether to be enrolled in the  
13  
14 trial. About the dental standards, the associated tooth should maintain normal pulp vitality. Or  
15  
16 it has received root canal therapy for more than 6 months. The intrabony defect existing  
17  
18 around the anterior teeth, the premolars, or at the mesial side of mandibular first molars will  
19  
20 be included to avoid the influence of furcation involvement. Patients with tumor,  
21  
22 uncontrolled systemic disease, history of receiving antibiotics in the past 3 months will be  
23  
24 excluded. The affected teeth with 3 degree mobility, furcation involvement, acute periapical  
25  
26 inflammation, and root fractures will not be enrolled.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

### 44 **Randomization and blinding**

45 The random sequence is produced through the random number table and the assignment is  
46  
47 saved in a sealed envelope. A research worker who does not know the trial process will be in  
48  
49 charge of the randomization. All subjects will be randomly assigned into two groups. Test  
50  
51 group: M-MIST plus Bio Oss Collagen<sup>®</sup>. Control group: M-MIST. All surgical operations  
52  
53 will be conducted by an experienced therapist in the dark of the assignment. Another two  
54  
55 members in the dark of the research schedule will respectively take charge of the clinical  
56  
57 examination and statistical analysis.  
58  
59  
60

## Interventions

The enrolled participants will receive periodontal clinical examination and take periapical radiographs. The surgical process will be performed as described in the literature<sup>15</sup>: if the width of the top of the gingival papilla is 2 mm or narrower, the simplified papilla preservation flap<sup>25</sup> will be performed to interdental papilla; if that is wider than 2 mm, the modified papilla preservation technique<sup>24</sup> will be used. Then the incision will extend along the gingival sulcus at the buccal side of the two adjacent teeth. Then a buccal flap will be opened to expose 1 to 2 mm buccal bone crest. With miniature blades and mini curettes, the granulation tissue will be taken out. The roots will be carefully planned with curettes. If the depth of the intrabony defect is 3 mm or deeper and the defect does not wrap to the lingual side of the tooth, the site will be finally enrolled in further examination and statistical analysis. If the intrabony defects do not meet the inclusion criteria, the surgery will be continued, but such defects will not be enrolled in further examination and statistical analysis. After thorough debridement and careful rinse with saline, the intrabony defect will be filled with Bio Oss Collagen<sup>®</sup>, abreast the buccal bone crest, in the test group. In the control group, intrabony defects will not be treated with any other materials. Finally, a single modified internal mattress suture will be performed to close the wound. After the surgery, if the tooth appears 2 to 3 degree mobility, the tooth will be splinted timely. The patients will be required to rinse with a 0.2% chlorhexidine solution for 1 week. The suture will be removed 1 week after the surgery.

The surgeries will be performed at the Periodontology Department, Peking University

1  
2 School and Hospital of Stomatology. An experienced periodontist with the help of operating  
3  
4  
5 microscope will conduct all operations.  
6  
7  
8  
9

## 10 11 12 **Examination**

13  
14  
15 At the baseline, all the enrolled subjects will receive periodontal examination by a calibrated  
16  
17 research worker. Relative periodontal indexes will include full mouth plaque score,<sup>26</sup> clinical  
18  
19 attachment loss of the involved teeth,<sup>27</sup> full mouth bleeding score,<sup>26</sup> gingival recession of the  
20  
21 involved teeth,<sup>12</sup> mobility of the involved teeth,<sup>26</sup> probing depth of the involved teeth,<sup>27</sup>  
22  
23 height of the gingival papilla,<sup>27</sup> periapical films of the interdental site.<sup>26</sup> During the surgery,  
24  
25 the defect anatomy including the depth and number of walls of the intrabony defects will be  
26  
27 examined by the operator. The patients will receive phone-call for re-examinations at 1 week,  
28  
29 1, 3, 6, 9, and 12 months after the surgery. At 1, 3, 6, 9, and 12 months after the surgery, full  
30  
31 mouth plaque score and height of the gingival papilla will be recorded by the same calibrated  
32  
33 examiner. At 12 months after the treatment, full mouth plaque score, clinical attachment gain  
34  
35 of the involved teeth, gingival recession, mobility, full mouth bleeding score, height of the  
36  
37 gingival papilla, probing depth of the involved teeth will be examined by the same examiner  
38  
39 and periapical films of the defect associated site will be taken. In addition, subjects will finish  
40  
41 a visual analog scale to evaluate the discomfort at 1 week after treatment. During the follow  
42  
43 up, complications will be recorded once they happen and treated accordingly. At  
44  
45 re-evaluation, if the oral hygiene is not good, we will clean the teeth by supragingival scaling  
46  
47 and reinforcement oral hygiene instruction. All the data will be recorded in the periodontal  
48  
49 examination charts and be registered and stored in computer. There are no data monitoring  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 committee in our hospital, in order to insure the correction and completion of data, two  
3  
4  
5 different researchers will take charge of the management and storage of data.  
6  
7  
8  
9  
10  
11  
12

### 13 **Sample size**

14  
15 The needed number of participants was calculated according to the formula:

$$16 \quad n1 = n2 = 2 \left[ \frac{\sigma(Z_{\alpha/2} + Z_{\beta})}{\delta} \right]^2$$

17  
18  
19  
20  
21 On the basis the previous literatures,<sup>15,33</sup> the difference of clinical attachment gain using  
22  
23 Bio Oss Collagen<sup>®</sup> or not ( $\delta$ ) was about 1.5 mm and the standard deviation ( $\sigma$ ) was about 1.4  
24  
25 mm. We set the power of test ( $\beta$ ) as 90% and the inspection level ( $\alpha$ ) as 0.05. After  
26  
27 calculation, 18 subjects will be needed for each group. Suppose that the rate of lost to follow  
28  
29 up is around 10%, 20 subjects will be needed for each group. Ultimately, at least 40 subjects  
30  
31 will be needed in all.  
32  
33  
34  
35  
36  
37  
38  
39  
40

### 41 **Statistical analysis**

42  
43  
44 One patient is identified as a data unit. If two or more infrabony defects go through the  
45  
46 surgery in one patient, only one defect nearest to the midline will be enrolled.<sup>34</sup> The paired  
47  
48 samples t test will be applied to detect any difference between baseline and 1 year  
49  
50 registrations. A general linear model will be performed to study the relationship between the  
51  
52 defect depth, number of bone walls, full mouth plaque score and full mouth bleeding score  
53  
54 with clinical attachment gain, probing depth reduction, and radiographic intrabony defect  
55  
56 depth change. The level of statistically significant difference will be installed at 0.05.  
57  
58  
59  
60

1  
2  
3 Statistical analysis will be computed using SPSS v26.0 software.  
4  
5  
6  
7  
8  
9

### 10 **Withdrawal**

11  
12 Participants will be told that they can quit the research at any moment. The withdrawal will  
13  
14 not influence their seeking for help from periodontists in our department in the future.  
15  
16  
17  
18  
19  
20  
21  
22

### 23 **Dissemination of data**

24  
25 Data of the present research will be registered in the International Clinical Trials Registry  
26  
27 Platform. Additionally, we will disseminate the results through scientific dental journals.  
28  
29  
30  
31  
32  
33  
34  
35

## 36 **DISCUSSION**

37  
38 For isolated intrabony defect, M-MIST could be an effective method, with an average clinical  
39  
40 attachment gain of 4.8 mm at 1 year after the surgery.<sup>15</sup> It allows access to root surface with  
41  
42 only the buccal flap opening, which is minimal invasive and further enhances wound  
43  
44 stability. But when bioactive materials, such as END and rhPDGF-BB, were used combined  
45  
46 with M-MIST, periodontal regenerative effects were not better.<sup>35,36</sup> EMD might not be an  
47  
48 ideal bioactive material in dealing with wide defects.<sup>37</sup> Bio Oss Collagen<sup>®</sup> is a bovine derived  
49  
50 xenograft containing profuse collagen, which can fit into different types of defects.<sup>31</sup> The  
51  
52 present research is designed to study the efficacy and potential applicability of M-MIST  
53  
54 combined with Bio Oss Collagen<sup>®</sup> for periodontal tissue regeneration of periodontal  
55  
56  
57  
58  
59  
60

1  
2 intrabony defects. If the results of M-MIST plus Bio Oss Collagen® turned out to be better  
3  
4 than those of M-MIST alone in terms of radiographic and clinical defect reductions, Bio Oss  
5  
6 Collagen® might be suggested as a combined application with M-MIST for periodontal tissue  
7  
8 regeneration of intrabony defects.  
9  
10  
11  
12  
13  
14  
15  
16  
17

## 18 **TRIAL STATUS**

19  
20 The trial protocol received ethics approval in March 2020 and was registered at International  
21  
22 Clinical Trials Registry Platform under the identifier number ChiCTR-2000030851 on 15  
23  
24 March 2020. The trial will begin after COVID-19 pandemic being controlled and is planned  
25  
26 to be completed in October 2021.  
27  
28  
29  
30  
31  
32  
33  
34  
35

## 36 **Acknowledgements**

37  
38 Not applicable  
39  
40  
41  
42  
43  
44  
45  
46

## 47 **Contributors**

48  
49 H-DZ, K-NL, C-RZ and J-XH proposed the concept of this work. C-RZ, K-NL and J-XH  
50  
51 designed the trial. C-RZ and H-DZ drafted the document. Z-GY, L-LM and YH revised the  
52  
53 part of randomization and calculation of sample size. K-NL and J-XH reviewed and finalized  
54  
55 the manuscript. All authors agreed the final version.  
56  
57  
58  
59  
60

## Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

## Competing interests

The authors declare that there is no conflict of interest

## Patient and public involvement

There were no patients or the public associated with the design or dissemination scheme of this work.

## Patient consent for publication

Not required.

## ORCID iD

Chu-Ren Zhang [http:// orcid. org/ 0000-0001-9070-7138](http://orcid.org/0000-0001-9070-7138)



## REFERENCES

- 1 Tonetti MS, Eickholz P, Loos BG, et al. Principles in prevention of periodontal diseases: consensus report of group 1 of the 11th European Workshop on Periodontology on effective prevention of periodontal and peri-implant diseases. *J Clin Periodontol* 2015;42Suppl16:5-11.
- 2 Ramseier CA, Anerud A, Dulac M, et al. Natural history of periodontitis: disease progression and tooth loss over 40 years. *J Clin Periodontol* 2017;44:1182-91.
- 3 GBD 2015 SDG Collaborators. Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. *Lancet* 2016;388:1813–50.
- 4 Berezow AB and Darveau RP. Microbial shift and periodontitis. *Periodontol 2000* 2011;55:36-47.
- 5 Serino G, Rosling B, Ramberg P, et al. Initial outcome and long-term effect of surgical and non-surgical treatment of advanced periodontal disease. *J Clin Periodontol* 2001;28:910–6.
- 6 Cortellini P and Tonetti MS. Clinical concepts for regenerative therapy in intrabony defects. *Periodontol 2000* 2015;68:282-307.
- 7 Matuliene G, Pjetursson BE, Salvi GE, et al. Influence of residual pockets on progression of periodontitis and tooth loss: results after 11 years of maintenance. *J Clin Periodontol* 2008;35:685–95.
- 8 Reynolds MA, Kao RT, Camargo PM, et al. Periodontal regeneration-intrabony defects: a consensus report from the AAP Regeneration Workshop. *J Periodontol* 2015;86Suppl2:105-7.

- 1  
2  
3 9 Sanz M, Tonetti MS, Zabalegui I, et al. Treatment of intrabony defects with enamel  
4  
5 matrix proteins or barrier membranes: Results from a multicenter practice-based clinical  
6  
7 trial. *J Periodontol* 2004;75:726–33.  
8  
9
- 10 Sculean A, Kiss A, Miliauskaite A, et al. Ten-year results following treatment of  
11  
12 intrabony defects with enamel matrix proteins and guided tissue regeneration. *J Clin*  
13  
14 *Periodontol* 2008;35:817–24.  
15  
16
- 17  
18 11 Paolantonio M, Femminella B, Coppolino E, et al. Autogenous periosteal barrier  
19  
20 membranes and bone grafts in the treatment of periodontal intrabony defects of  
21  
22 single-rooted teeth: A 12-month reentry randomized controlled clinical trial. *J*  
23  
24 *Periodontol* 2010;81:1587–95.  
25  
26
- 27  
28 12 Cortellini P, Buti J, Pini Prato G, et al. Periodontal regeneration compared with access  
29  
30 flap surgery in human intra-bony defects 20-year follow-up of a randomized clinical  
31  
32 trial: tooth retention, periodontitis recurrence and costs. *J Clin Periodontol*  
33  
34 2017;44:59-66.  
35  
36
- 37  
38 13 Wachtel H, Schenk G, Böhm S, et al. Microsurgical access flap and enamel matrix  
39  
40 derivative for the treatment of periodontal intrabony defects: A controlled clinical study.  
41  
42 *J Clin Periodontol* 2003;30:496–504.  
43  
44
- 45  
46 14 Cortellini P and Tonetti MS. Minimally invasive surgical technique and enamel matrix  
47  
48 derivative in intrabony defects. I: Clinical outcomes and morbidity. *J Clin Periodontol*  
49  
50 2007;34:1082–8.  
51  
52
- 53  
54 15 Cortellini P and Tonetti MS. Improved wound stability with a modified minimally  
55  
56 invasive surgical technique in the regenerative treatment of isolated interdental intrabony  
57  
58 defects. *J Clin Periodontol* 2009;36:157–63.  
59  
60


- 1  
2  
3 16 Takeda K, Mizutani K, Matsuura T, et al. Periodontal regenerative effect of enamel  
4  
5 matrix derivative in diabetes. *PLoS One* 2018;13:e0207201.  
6  
7  
8 17 Sali DD and Pauline George J. Demineralized freeze dried bone allograft with amniotic  
9  
10 membrane in the treatment of periodontal intrabony defects - 12 month randomized  
11  
12 controlled clinical trial. *J Periodontol* 2016;11:1-18.  
13  
14  
15 18 Li F, Yu F, Xu X, et al. Evaluation of Recombinant Human FGF-2 and PDGF-BB in  
16  
17 Periodontal Regeneration: A Systematic Review and Meta-Analysis. *Sci Rep* 2017;7:65.  
18  
19  
20 19 Nevins ML, Camelo M, Rebaudi A, et al. Three-dimensional micro-computed  
21  
22 tomographic evaluation of periodontal regeneration: a human report of intrabony defects  
23  
24 treated with Bio-Oss collagen. *Int J Periodontics Restorative Dent* 2005;25:365-73.  
25  
26  
27  
28 20 Aimetti M, Romano F, Pigella E, et al. Treatment of wide, shallow, and predominantly  
29  
30 1-wall intrabony defects with a bioabsorbable membrane: A randomized controlled  
31  
32 clinical trial. *J Periodontol* 2005;6:1354-61.  
33  
34  
35  
36 21 Nickles K, Ratka-Krüger P, Neukranz E, et al. Open flap debridement and guided tissue  
37  
38 regeneration after 10 years in infrabony defects. *J Clin Periodontol* 2009;36:976-83.  
39  
40  
41 22 Graziani F, Gennai S, Cei S, et al. Clinical performance of access flap surgery in the  
42  
43 treatment of the intrabony defect. A systematic review and meta-analysis of randomized  
44  
45 clinical trials. *J Clin Periodontol* 2012;39:145-56.  
46  
47  
48  
49 23 Harrel SK and Rees TD. Granulation tissue removal in routine and minimally invasive  
50  
51 procedures. *Compend Contin Educ Dent* 1995;16:960,962,964passim.  
52  
53  
54 24 Cortellini P, Prato GP and Tonetti MS. The Modified Papilla Preservation Technique. A  
55  
56 New Surgical Approach for Interproximal Regenerative Procedures. *J Periodontol*  
57  
58 1995;66:261-6.  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 25 Cortellini P, Prato GP and Tonetti MS. The Simplified Papilla Preservation Flap. a Novel Surgical Approach for the Management of Soft Tissues in Regenerative Procedures. *Int J Periodontics Restorative Dent* 1999;19:589-99.
- 26 Cortellini P and Tonetti MS. A minimally invasive surgical technique with an enamel matrix derivative in the regenerative treatment of intra-bony defects: a novel approach to limit morbidity. *J Clin Periodontol* 2007;34:87-93.
- 27 Cortellini P, Nieri M, Prato GP, et al. Single minimally invasive surgical technique with an enamel matrix derivative to treat multiple adjacent intra-bony defects: Clinical outcomes and patient morbidity. *J Clin Periodontol* 2008;35:605-13.
- 28 Aimetti M, Ferrarotti F, Mariani GM, et al. A novel flapless approach versus minimally invasive surgery in periodontal regeneration with enamel matrix derivative proteins: a 24-month randomized controlled clinical trial. *Clin Oral Investig* 2017;21:327-37.
- 29 Liu S, Hu B, Zhang Y, et al. Minimally Invasive Surgery Combined with Regenerative Biomaterials in Treating Intra-Bony Defects: A Meta-Analysis. *PLoS One* 2016;11:e0147001.
- 30 Palachur D, Prabhakara Rao KV, Murthy KR, et al. A comparative evaluation of bovine-derived xenograft (Bio-Oss Collagen) and type I collagen membrane (Bio-Gide) with bovine-derived xenograft (Bio-Oss Collagen) and fibrin fibronectin sealing system (TISSEEL) in the treatment of intrabony defects: A clinico-radiographic study. *J Indian Soc Periodontol* 2014;18:336-43.
- 31 Sculean A, Chiantella GC, Windisch P, et al. Healing of intra-bony defects following treatment with a composite bovine-derived xenograft (Bio-Oss Collagen) in combination with a collagen membrane (Bio-Gide PERIO). *J Clin Periodontol* 2005;32:720-4.

- 1  
2  
3 32 Tonetti MS, Greenwell H and Kornman KS. Staging and grading of periodontitis:  
4  
5 framework and proposal of a new classification and case definition. *J Clin Periodontol*  
6  
7 2018;45Suppl20:149–61.  
8  
9
- 10 33 De Bruyckere T, Eghbali A, Younes F, et al. A 5-year prospective study on regenerative  
11  
12 periodontal therapy of infrabony defects using minimally invasive surgery and a  
13  
14 collagen-enriched bovine-derived xenograft. *Clin Oral Investig* 2018;22:1235-42.  
15  
16
- 17 34 Cosyn J, Cleymaet R, Hanselaer L, et al. Regenerative periodontal therapy of infrabony  
18  
19 defects using minimally invasive surgery and a collagen-enriched bovine-derived  
20  
21 xenograft: a 1-year prospective study on clinical and aesthetic outcome. *J Clin*  
22  
23 *Periodontol* 2012;39:979–86.  
24  
25
- 26 35 Cortellini P and Tonetti MS. Clinical and radiographic outcomes of the modified  
27  
28 minimally invasive surgical technique with and without regenerative materials: a  
29  
30 randomized-controlled trial in intra-bony defects. *J Clin Periodontol* 2011;38:365-73.  
31  
32  
33
- 34 36 Mishra A, Avula H, Pathakota KR, et al. Efficacy of modified minimally invasive  
35  
36 surgical technique in the treatment of human intrabony defects with or without use of  
37  
38 rhPDGF-BB gel: a randomized controlled trial. *J Clin Periodontol* 2013;40:172-9.  
39  
40  
41  
42
- 43 37 Tonetti MS, Lang NP, Cortellini P, et al. Enamel matrix proteins in the regenerative  
44  
45 therapy of deep intrabony defects. *J Clin Periodontol* 2002;29:317–25.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1. The framework of the trial and CONSORT flow chart



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. The framework of the trial and CONSORT flow chart

80x45mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Page
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	3
Protocol version	3	Date and version identifier	3
Funding	4	Sources and types of financial, material, and other support	15
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1,14
	5b	Name and contact information for the trial sponsor	1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	14
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	
<b>Introduction</b>			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4,5,6
	6b	Explanation for choice of comparators	6
Objectives	7	Specific objectives or hypotheses	6



1				
2	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	7-10
3				
4				
5				
6				
7				
8	<b>Methods: Participants, interventions, and outcomes</b>			
9				
10	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	7
11				
12				
13				
14				
15	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	7,8
16				
17				
18				
19				
20	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	9
21				
22				
23				
24				
25		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	
26				
27				
28				
29				
30		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	10
31				
32				
33				
34				
35		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	11
36				
37				
38	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	6
39				
40				
41				
42				
43				
44				
45				
46	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	7
47				
48				
49				
50				
51				
52	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	11
53				
54				
55				
56	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	7
57				
58				
59				
60	<b>Methods: Assignment of interventions (for controlled trials)</b>			

## Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	8
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	8
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	8
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	8
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	

**Methods: Data collection, management, and analysis**

Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	9
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	9
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	11
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	12
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	

1				
2		20c	Definition of analysis population relating to	
3			protocol non-adherence (eg, as randomised analysis), and any	
4			statistical methods to handle missing data (eg, multiple imputation)	
5				
6				
7				
8				
9				
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				
21				
22				
23				
24				
25				
26				
27				
28				
29				
30				
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

**Methods: Monitoring**

Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	11
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	12
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	11
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	

**Ethics and dissemination**

Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	7
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	7
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	7
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	15
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	10

1				
2	Ancillary and	30	Provisions, if any, for ancillary and post-trial care,	
3	post-trial care		and for compensation to those who suffer harm from trial participation	
4				
5	Dissemination	31a	Plans for investigators and sponsor to	13
6	policy		communicate trial results to participants, healthcare professionals,	
7			the public, and other relevant groups (eg, via publication, reporting in	
8			results databases, or other data sharing arrangements), including any	
9			publication restrictions	
10				
11		31b	Authorship eligibility guidelines and any intended	15
12			use of professional writers	
13				
14		31c	Plans, if any, for granting public access	13
15			to the full protocol, participant-level dataset, and statistical code	
16				
17				
18				
19	<b>Appendices</b>			
20				
21	Informed consent	32	Model consent form and other related	
22	materials		documentation given to participants and authorised surrogates	
23				
24	Biological	33	Plans for collection, laboratory evaluation,	
25	specimens		and storage of biological specimens for genetic or molecular analysis	
26			in the current trial and for future use in ancillary studies, if applicable	
27				

---

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

# BMJ Open

## Modified minimally invasive surgical technique plus Bio-Oss® Collagen for regenerative therapy of isolated interdental intrabony defects: study protocol for a randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-040046.R1
Article Type:	Protocol
Date Submitted by the Author:	14-Jul-2020
Complete List of Authors:	Zhang, Churen; Peking University School of Stomatology, Zhang, Haidong; Peking University School of Stomatology, Department of Periodontology Yue, Zhaoguo; Peking University School of Stomatology, Department of Periodontology Miao, Lili; Peking University School of Stomatology, Department of Periodontology Han, Ye; Peking University School of Stomatology, Department of Periodontology Liu, Kaining; Peking University School of Stomatology, Department of Periodontology Hou, Jianxia; Peking University School of Stomatology, Department of Periodontology
<b>Primary Subject Heading</b>:	Dentistry and oral medicine
Secondary Subject Heading:	Dentistry and oral medicine, Infectious diseases, Surgery
Keywords:	ORAL & MAXILLOFACIAL SURGERY, PLASTIC & RECONSTRUCTIVE SURGERY, Oral & maxillofacial surgery < SURGERY, Clinical trials < THERAPEUTICS

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Modified minimally invasive surgical technique plus Bio-Oss®**  
4  
5 **Collagen for regenerative therapy of isolated interdental**  
6  
7 **intra-bony defects: study protocol for a randomised controlled**  
8  
9 **trial**  
10  
11  
12  
13  
14

15 the corresponding author: Dr. Kai-Ning Liu and Dr. Jian-Xia Hou

16  
17  
18 Address: 22 Zhongguancun South Avenue, Haidian District, Beijing 100081, People's  
19  
20 Republic of China.

21  
22  
23 Email address: [liukainingbjmu@163.com](mailto:liukainingbjmu@163.com) and [jxhou@163.com](mailto:jxhou@163.com)  
24  
25  
26  
27

28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Chu-Ren Zhang<sup>1</sup>, Hai-Dong Zhang<sup>1</sup>, Zhao-Guo Yue<sup>1</sup>, Li-Li Miao<sup>1</sup>, Ye Han<sup>1</sup>, Kai-Ning Liu<sup>1</sup>  
and Jian-Xia Hou<sup>1</sup>

<sup>1</sup>Department of Periodontology, Peking University School and Hospital of Stomatology and  
National Engineering Laboratory for Digital and Material Technology of Stomatology and  
Beijing Key Laboratory of Digital Stomatology, 22 Zhongguancun South Avenue, Haidian  
District, Beijing 100081, People's Republic of China.

the total number of words (except abstract, references, tables and figures): 2571.

## Abstract

### Introduction

Periodontal regeneration surgery has been widely used to deal with intra-bony defects.

Modified minimally invasive surgical technique (M-MIST) is designed to deal with isolated

1  
2 interdental intrabony defects, having achieved satisfactory periodontal regenerative effect.  
3  
4  
5 Bio-Oss® Collagen, as a bioactive material, has been applied to periodontal regeneration. It is  
6  
7 similar to human cancellous bone, with the ability to promote bone formation; further, it has  
8  
9 exceptional plasticity and spatial stability. The combination of different materials and  
10  
11 techniques has become a research hotspot in recent years. By combining the superiority of  
12  
13 regeneration technology and materials, better regenerative effect can be achieved. This study  
14  
15 will search for differences between M-MIST combined with Bio-Oss® Collagen and M-MIST  
16  
17 exclusively in regeneration therapy for intrabony defects.  
18  
19  
20  
21  
22

23 **Methods and Analysis:** The present research is designed as a two group parallel  
24  
25 randomised controlled trial. The needed number of participants is 40. The patients will be  
26  
27 randomly assigned to two groups, 20 participants in each group, for further periodontal  
28  
29 regenerative surgery. Test group: M-MIST plus Bio-Oss® Collagen. Control group: M-MIST.  
30  
31 After 12 months, the measurement indexes will be recorded; these will include clinical  
32  
33 attachment gain and radiographic intrabony defect depth change, as the primary results, and  
34  
35 secondary outcomes of full-mouth plaque scores, probing depth, full-mouth bleeding scores,  
36  
37 gingival recession, mobility, gingival papilla height, and visual analogue scale (VAS). The  
38  
39 paired samples *t*-test will be applied to detect any difference between baseline and one year  
40  
41 registrations. A general linear model will be performed to study the relationship between the  
42  
43 second and the primary outcome.  
44  
45  
46  
47  
48  
49  
50

51 **Ethics and Dissemination:** The present research has received approval from the Ethics  
52  
53 Committee of Peking University School and Hospital of Stomatology  
54  
55 (PKUSSIRB-202053002). Data of the present research will be registered with the  
56  
57 International Clinical Trials Registry Platform. Additionally, we will disseminate the results  
58  
59  
60



1  
2 through scientific dental journals.  
3  
4  
5

6 **Trial registration number:** ChiCTR-2000030851.  
7  
8

9  
10 **Protocol version:** Protocol Version 4, 07.14.2020.  
11  
12

### 13 **Strengths and limitations of this study:** 14

15 This trial is designed as a randomised, examiner-blind clinical trial.  
16

17  
18 The trial will be the first clinical study to compare the periodontal regenerative effect of  
19 M-MIST plus Bio-Oss® Collagen and M-MIST exclusively in isolated interdental intrabony  
20 defects.  
21  
22  
23  
24

25  
26 The results of this trial might provide a new option for periodontal regeneration of isolated  
27 interdental intrabony defects.  
28  
29

30  
31 The follow-up in the trial will last for one year.  
32

33  
34 The outcome of this study will not be applied to patients with systemic disease.  
35

36 **Key words:** Intrabony defect; periodontal regenerative therapy; Bio-Oss® Collagen;  
37 modified minimally invasive surgical technique.  
38  
39  
40  
41  
42  
43  
44  
45  
46

## 47 **INTRODUCTION** 48

49 Periodontal disease is an inflammatory disease, with a high incidence around the teeth. It can  
50 lead to loss of periodontal attachment and alveolar bone, and even to tooth loss.<sup>1,2</sup> Periodontal  
51 disease is caused by multiple factors, of which the initial factor is the interaction between the  
52 biofilm and the immune response.<sup>3</sup> Periodontal pathogens play a key role in the pathogenesis  
53 and development of periodontal and systemic diseases, including diabetes and cardiovascular  
54  
55  
56  
57  
58  
59  
60

1  
2 diseases, which can influence the development of periodontal disease.<sup>4</sup> It is reported that  
3  
4  
5 periodontitis is one of the most universal diseases around the world.<sup>5</sup> Scaling and root  
6  
7  
8 planning (SRP) is the essential therapy for every patient.<sup>6</sup> However, for teeth with deep  
9  
10  
11 periodontal pockets, SRP cannot not achieve a more therapeutic effect than surgery.<sup>7</sup> After  
12  
13  
14 periodontal initial therapy, the residual deep pockets have often been associated with  
15  
16  
17 intrabony defects, identified as a clinical challenge.<sup>8</sup> The intrabony defects may result in  
18  
19  
20 unmanageable inflammation, and ultimately to tooth loss.<sup>9</sup> Therefore, intrabony defects are  
21  
22  
23 generally regarded as surgical indications.<sup>10</sup>

24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Periodontal regeneration surgery has been widely applied to deal with intrabony defects with the purpose of reforming the periodontal attachment in hopes of saving the involved teeth.<sup>11-14</sup> In the past 20 years, the development of periodontal regeneration therapy has been reflected mainly in two aspects. First, surgical design and techniques have been studied, especially minimally invasive surgery.<sup>15-20</sup> Second, considerable progress has been made in regenerative materials, such as enamel matrix derivative (EMD),<sup>18</sup> demineralized freeze-dried bone allograft (DFDBA),<sup>19</sup> recombinant human platelet-derived growth factor BB (rhPDGF-BB),<sup>20</sup> and spongy bone with collagen (Bio-Oss® Collagen).<sup>21</sup> These methods offer more advantages than simple flap debridement in increasing clinical attachment and decreasing probing depth of the affected teeth.<sup>22,23</sup> However, common complications, such as the exposure of barrier membrane and embedded material, have contributed to poor clinical results of periodontal regeneration surgery.<sup>24</sup>

54  
55  
56  
57  
58  
59  
60  
To solve this problem, many periodontal surgical designs and techniques have been proposed and continually improved on.<sup>25-28</sup> As early as in 1995, Harrel and Ress<sup>25</sup> suggested applying minimally invasive surgery to periodontal surgical treatment, whose key points were

1  
2 small incision, small flap, and reduction of damage to soft and hard tissues. In 1995 and  
3  
4  
5 1999, Cortellini<sup>26,27</sup> proposed the papilla preservation techniques to preserve interdental soft  
6  
7 tissues as completely as possible and isolate the operative area from the oral environment. On  
8  
9 this basis, to further improve the surgical effect, the concept of minimally invasive surgery  
10  
11 was proposed and gradually improved upon. In 2007, Cortellini and Tonetti<sup>28</sup> proposed a  
12  
13 minimally invasive surgical technique (MIST) to deal with periodontal intrabony defects for  
14  
15 more periodontal tissue regeneration. This technique was designed to reduce surgical trauma,  
16  
17 operative time, and postoperative discomfort.<sup>28</sup> A number of clinical studies<sup>16,29</sup> have  
18  
19 confirmed its effectiveness and advantages of the technique. In 2009, Cortellini and Tonetti<sup>17</sup>  
20  
21 further designed a modified minimally invasive surgical technique (M-MIST). This method  
22  
23 only opened the tiny buccal flap to ensure adequate blood supply, tighter primary wound  
24  
25 closure and lower risk of bacterial infection.  
26  
27  
28  
29  
30  
31  
32

33  
34 In recent years, the combination of different materials and techniques has become a  
35  
36 research hotspot.<sup>30</sup> By combining the advantages of regeneration technology and materials,  
37  
38 better regenerative results can be achieved.<sup>31</sup> M-MIST only opens a small flap on the buccal  
39  
40 side to achieve minimal interdental passage, saving the palatal soft tissue.<sup>17</sup> Bio-Oss<sup>®</sup>  
41  
42 Collagen is similar to human cancellous bone, with the ability to promote bone formation.<sup>32</sup>  
43  
44 Bio-Oss<sup>®</sup> Collagen, with outstanding plasticity and spatial stability,<sup>33</sup> is suitable for the small  
45  
46 field of vision resulting from M-MIST. Therefore, we plan to research the therapeutic effect  
47  
48 of M-MIST combined with Bio-Oss<sup>®</sup> Collagen and the use of M-MIST exclusively for  
49  
50 periodontal tissue regeneration of isolated interdental intrabony defects. The presumption was  
51  
52 raised that combining M-MIST and Bio-Oss<sup>®</sup> Collagen would lead to a better result in  
53  
54 periodontally regenerating intrabony defects than M-MIST alone. The practicability,  
55  
56  
57  
58  
59  
60

1 applicability and extensibility of the combination will be investigated in the present study.  
2  
3  
4  
5 The primary outcomes were clinical attachment gain and radiographic bone-filling the  
6  
7 intrabony defect, which would be recorded by clinical examination, periapical radiographs  
8  
9 and cone beam computed tomography. The clinical attachment gain and bone filling  
10  
11 represent periodontal tissue regeneration.<sup>17</sup> The secondary outcomes were probing depth,  
12  
13 full-mouth plaque scores, full-mouth bleeding scores, gingival recession, mobility, height of  
14  
15 the gingival papilla, and visual analogue scale (VAS). These indexes represent the  
16  
17 inflammatory characteristics of periodontal tissue.<sup>28</sup> The present article describes the design  
18  
19 of the trial.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

## 31 **METHODS AND ANALYSIS**

32  
33 This research is a randomised controlled trial with two parallel groups. It will be carried out  
34  
35 according to the basis of the World Medical Association Declaration of Helsinki. Patients  
36  
37 with stage III or IV periodontitis,<sup>34</sup> (details in the supplemental material) needing periodontal  
38  
39 regenerative treatment for isolated intrabony defects are the potential subjects. This study will  
40  
41 be undertaken at Peking University School and Hospital of Stomatology (Beijing, China).  
42  
43  
44 The present research has received approval from the Ethics Committee of Peking University  
45  
46 School and Hospital of Stomatology (PKUSSIRB-202053002), and it is registered with the  
47  
48 International Clinical Trials Registry Platform (ID: ChiCTR-2000030851). The research  
49  
50 framework is shown in Figure 1.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Participant selection

All participants will come from the Periodontology Department at Peking University School and Hospital of Stomatology. At re-evaluation after periodontal initial therapy, if the subject is found to have isolated intrabony defects, he or she will be informed about the study. The potential subjects will receive information about the research. The subjects will be incorporated into this trial only after their signature has been obtained. The personal information of the consent form will be confidentially stored in our department.

As regards the patient characteristics, the following criteria should be met: (1) age 18 to 75 years; (2) both genders will be considered for selection in the study; (3) patients with stage III or IV periodontitis at least two months after periodontal initial therapy; (4) good compliance; (5) good oral hygiene; (6) full-mouth plaque score and full-mouth bleeding score each less than 30%; (7) systemically healthy. The intrabony defect should be an isolated intrabony defect of more than 3 mm in depth, combined with more than a 5 mm probing depth and attachment loss. In addition, the intrabony defect should not exceed in area the lingual surface area of the root. The morphology of the intrabony defect will be detected during the operation and finally determined whether the patient would be enrolled in the trial. The associated tooth should either maintain normal pulp vitality or it should have undergone root canal therapy for at least six months. The intrabony defect existing around the anterior teeth, the premolars or at the mesial side of mandibular first molars will be included to avoid the influence of furcation involvement. Patients with tumours, systemic diseases, or a history of receiving antibiotics in the past three months will be excluded. The affected teeth with 3° mobility, furcation involvement, acute periapical inflammation, or root fractures will not be enrolled.

## Randomisation and blinding

The random sequence is produced through a random number table and the assignment is saved in a sealed envelope. A research worker unaware of the trial process will be in charge of the randomisation. All subjects will be randomly assigned to two groups. Test group: M-MIST combined with Bio-Oss® Collagen. Control group: M-MIST. All surgical operations will be performed by an experienced therapist in the dark of the assignment. Another two members in the dark of the research plan will respectively take charge of the clinical examination and statistical analysis.

## Interventions

The enrolled participants will receive a periodontal clinical examination. They will have periapical radiographs and cone beam computed tomography taken. The surgical process will be performed as described in the literature<sup>17</sup>: if the width of the top of the gingival papilla is 2 mm or narrower, the simplified papilla preservation flap<sup>27</sup> will be performed; if it is wider than 2 mm, the modified papilla preservation technique<sup>26</sup> will be used. Then the incision will extend along the gingival sulcus on the buccal side of the two adjacent teeth, and a buccal flap will be reflected to expose 1 to 2 mm of buccal bone crest. With miniature blades and mini curettes, the granulation tissue will be curetted and the roots will be carefully planned with curettes. If the depth of the intrabony defect is 3 mm or more and the defect does not contain a lingual intrabony component, the site will be finally enrolled for further examination and statistical analysis. If the intrabony defects do not meet the inclusion

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

criteria, the surgery will be continued, but such defects will not be enrolled for further examination or statistical analysis. After thorough debridement and careful rinsing with saline solution, the intrabony defect will be filled with Bio-Oss® Collagen, level with the buccal bone crest, in the test group. In the control group, intrabony defects will not be treated with any other materials. Finally, a vertical mattress suture will be performed to close the wound. Periapical films of the defect associated site will be taken immediately after the surgery. If the tooth appears to have 2 to 3° mobility after the surgery, the tooth will be promptly splinted. The patients will be required to rinse with a 0.2% chlorhexidine solution for one week, and the suture will be removed one week after surgery.

The surgeries will be performed at the Periodontology Department, Peking University School and Hospital of Stomatology. An experienced periodontist with the help of an operating microscope will perform all operations.

### Examination

At baseline, all the enrolled subjects will receive a periodontal examination by two experienced research professionals who have passed the inter-examiner agreement exam. Relative periodontal indexes will include full-mouth plaque score,<sup>28</sup> clinical attachment loss of the involved teeth,<sup>29</sup> full-mouth bleeding score,<sup>28</sup> gingival recession of the involved teeth,<sup>14</sup> mobility of the involved teeth,<sup>28</sup> probing depth of the involved teeth,<sup>29</sup> height of the gingival papilla,<sup>29</sup> periapical films and cone beam computed tomography of the interdental site.<sup>28</sup> During the surgery, the defect anatomy, including the depth and number of walls of the intrabony defects, will be examined by the operator. The patients will receive a phone-call for

1  
2 re-examinations at 1 week and 1, 3, 6, 9, and 12 months post-surgery. At 1, 3, 6, 9, and 12  
3  
4 months post-surgery, a full-mouth plaque score and gingival papilla height will be recorded  
5  
6  
7 by the same calibrated examiners. At 12 months post-treatment, a full-mouth plaque score,  
8  
9 clinical attachment gain of the involved teeth, gingival recession, mobility, full-mouth  
10  
11 bleeding score, gingival papilla height, probing depth of the involved teeth will be examined  
12  
13  
14 by the same examiners. Periapical films and cone beam computed tomography of the defect  
15  
16 associated site will be taken 6 and 12 months post-surgery. In addition, subjects will finish a  
17  
18 VAS to evaluate the discomfort after 1 week of treatment. During the follow-up,  
19  
20 complications will be recorded and treated once they happen. At re-evaluation, if the oral  
21  
22 hygiene is deficient, we will clean the teeth by supragingival scaling and reinforcing oral  
23  
24 hygiene instruction. All the data will be recorded in the periodontal examination charts and  
25  
26 be registered and stored in the computer. There is no data monitoring committee in our  
27  
28 hospital, so to ensure the correction and integrity of data, two different researchers will take  
29  
30 charge of the management and storage of data.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

#### 44 **Sample size**

45  
46 The needed number of participants was calculated according to the formula:

$$47 \quad n1 = n2 = 2 \left[ \frac{\sigma(Z_{\alpha/2} + Z_{\beta})}{\delta} \right]^2$$

48  
49  
50  
51 On the basis of previous literature,<sup>17,35</sup> the difference of clinical attachment gain using  
52  
53 Bio-Oss® Collagen or not ( $\delta$ ) was about 1.5 mm and the standard deviation ( $\sigma$ ) was about 1.4  
54  
55 mm. The power of test ( $\beta$ ) is set as 10% and the inspection level ( $\alpha$ ) is set as 0.05. After  
56  
57 calculation, 18 subjects will be needed for each group. Suppose that the rate of subjects lost  
58  
59  
60



1  
2 during follow up is around 10%, 20 subjects will be needed for each group. Ultimately, at  
3  
4  
5 least 40 subjects will be needed in all.  
6  
7  
8  
9  
10

### 11 12 **Statistical analysis**

13  
14  
15 One patient will be identified as a data unit. If two or more intrabony defects go through the  
16  
17 surgery in one patient, only one defect nearest to the midline will be enrolled.<sup>36</sup> The paired  
18  
19 samples *t*-test will be applied to detect any difference between baseline and one year  
20  
21 registrations. A general linear model will be performed to study the relationship between the  
22  
23 defect depth, number of bony walls, full-mouth plaque score and full-mouth bleeding score  
24  
25 with clinical attachment gain, probing depth reduction and radiographic intrabony defect  
26  
27 depth change. The level of statistically significant difference will be set at 0.05. Statistical  
28  
29 analysis will be done using SPSS version 26.0 software.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

### 41 **Withdrawal**

42  
43  
44 Participants will be told that they can quit the research at any time. The withdrawal will not  
45  
46 influence their receiving help from departmental periodontists in the future.  
47  
48  
49  
50  
51

### 52 **Dissemination of data**

53  
54  
55  
56  
57 Data from the present research will be registered with the International Clinical Trials  
58  
59 Registry Platform. Additionally, we will disseminate the results through scientific dental  
60

1  
2  
3 journals.  
4  
5  
6  
7  
8  
9

## 10 **DISCUSSION**

11  
12 For an isolated intrabony defect, M-MIST could be an effective treatment method, with an  
13 average clinical attachment gain of 4.8 mm at 1 year post-surgery.<sup>17</sup> It allows access to the  
14 root surface with only the buccal flap opening, which is minimally invasive and further  
15 enhances wound stability. However, when bioactive materials, such as EMD and  
16 rhPDGF-BB, were used combined with M-MIST, periodontal regenerative effects were not  
17 better.<sup>37,38</sup> EMD might not be an ideal bioactive material in dealing with wide defects.<sup>39</sup>  
18 Bio-Oss<sup>®</sup> Collagen is a bovine derived xenograft containing profuse collagen that can fit into  
19 different types of defects.<sup>33</sup> The present research is designed to study the effectiveness and  
20 potential applicability of M-MIST combined with Bio-Oss<sup>®</sup> Collagen for tissue regeneration  
21 of periodontal intrabony defects. If the results of M-MIST combined with Bio-Oss<sup>®</sup> Collagen  
22 turned out to be better than those of M-MIST alone in terms of radiographic and clinical  
23 defect improvement, Bio-Oss<sup>®</sup> Collagen might be considered as a combined application with  
24 M-MIST for periodontal tissue regeneration of intrabony defects.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

## 51 **TRIAL STATUS**

52 The trial protocol received ethics approval in March 2020 and was registered at the  
53 International Clinical Trials Registry Platform (ID: ChiCTR-2000030851) on March 15,  
54 2020. The trial will begin after the COVID-19 pandemic has been controlled; it is scheduled  
55  
56  
57  
58  
59  
60

1  
2  
3 to be completed in October, 2021.  
4  
5  
6  
7  
8  
9

## 10 **Acknowledgements**

11  
12  
13 Not applicable  
14  
15  
16  
17  
18  
19

## 20 **Contributors**

21  
22  
23 H-DZ, K-NL, C-RZ and J-XH proposed the concept of this work. C-RZ, K-NL and J-XH  
24  
25 designed the trial. C-RZ and H-DZ drafted the document. Z-GY, L-LM and YH revised the  
26  
27 part on randomisation and calculation of the sample size. K-NL and J-XH reviewed and  
28  
29 finalised the manuscript. All authors agreed to the final version.  
30  
31  
32  
33  
34  
35  
36  
37  
38

## 39 **Funding**

40  
41 This research received no specific grant from any funding agency in the public, commercial,  
42  
43 or not-for-profit sectors.  
44  
45  
46  
47  
48  
49  
50

## 51 **Competing interests**

52  
53  
54 The authors declare that there is no conflict of interest  
55  
56  
57  
58  
59  
60

## Patient and public involvement

Neither patients nor the public were associated with either the design or dissemination scheme of this work.

## Patient consent for publication

Not required.

## ORCID iD

Chu-Ren Zhang [http:// orcid. org/ 0000-0001-9070-7138](http://orcid.org/0000-0001-9070-7138)

## REFERENCES

- 1 Tonetti MS, Eickholz P, Loos BG, et al. Principles in prevention of periodontal diseases: consensus report of group 1 of the 11th European Workshop on Periodontology on effective prevention of periodontal and peri-implant diseases. *J Clin Periodontol* 2015;42Suppl16:5-11.
- 2 Ramseier CA, Anerud A, Dulac M, et al. Natural history of periodontitis: disease progression and tooth loss over 40 years. *J Clin Periodontol* 2017;44:1182-91.
- 3 Meyle J, Chapple I. Molecular aspects of the pathogenesis of periodontitis. *Periodontol 2000* 2015;69:7-17.
- 4 Hasturk H, Kantarci A. Activation and resolution of periodontal inflammation and its

- 1  
2 systemic impact. *Periodontol 2000* 2015;69:255–73.  
3  
4
- 5 GBD 2015 SDG Collaborators. Measuring the health-related Sustainable Development  
6  
7 Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study  
8  
9 2015. *Lancet* 2016;388:1813–50.  
10  
11
- 12  
13 6 Berezow AB and Darveau RP. Microbial shift and periodontitis. *Periodontol 2000*  
14  
15 2011;55:36-47.  
16  
17
- 18 7 Serino G, Rosling B, Ramberg P, et al. Initial outcome and long-term effect of surgical  
19  
20 and non-surgical treatment of advanced periodontal disease. *J Clin Periodontol*  
21  
22 2001;28:910–6.  
23  
24
- 25  
26 8 Cortellini P and Tonetti MS. Clinical concepts for regenerative therapy in intrabony  
27  
28 defects. *Periodontol 2000* 2015;68:282-307.  
29  
30
- 31 9 Matuliene G, Pjetursson BE, Salvi GE, et al. Influence of residual pockets on progression  
32  
33 of periodontitis and tooth loss: results after 11 years of maintenance. *J Clin Periodontol*  
34  
35 2008;35:685–95.  
36  
37
- 38  
39 10 Reynolds MA, Kao RT, Camargo PM, et al. Periodontal regeneration-intrabony defects:  
40  
41 a consensus report from the AAP Regeneration Workshop. *J Periodontol*  
42  
43 2015;86Suppl2:105-7.  
44  
45
- 46  
47 11 Sanz M, Tonetti MS, Zabalegui I, et al. Treatment of intrabony defects with enamel  
48  
49 matrix proteins or barrier membranes: Results from a multicenter practice-based clinical  
50  
51 trial. *J Periodontol* 2004;75:726–33.  
52  
53
- 54  
55 12 Sculean A, Kiss A, Miliauskaite A, et al. Ten-year results following treatment of  
56  
57 intrabony defects with enamel matrix proteins and guided tissue regeneration. *J Clin*  
58  
59 *Periodontol* 2008;35:817–24.  
60

- 1  
2  
3 13 Paolantonio M, Femminella B, Coppolino E, et al. Autogenous periosteal barrier  
4  
5 membranes and bone grafts in the treatment of periodontal intrabony defects of  
6  
7 single-rooted teeth: A 12-month reentry randomized controlled clinical trial. *J*  
8  
9 *Periodontol* 2010;81:1587–95.  
10  
11  
12  
13 14 Cortellini P, Buti J, Pini Prato G, et al. Periodontal regeneration compared with access  
14  
15 flap surgery in human intra-bony defects 20-year follow-up of a randomized clinical  
16  
17 trial: tooth retention, periodontitis recurrence and costs. *J Clin Periodontol*  
18  
19 2017;44:59-66.  
20  
21  
22  
23 24 Wachtel H, Schenk G, Böhm S, et al. Microsurgical access flap and enamel matrix  
25  
26 derivative for the treatment of periodontal intrabony defects: A controlled clinical study.  
27  
28 *J Clin Periodontol* 2003;30:496–504.  
29  
30  
31 32 Cortellini P and Tonetti MS. Minimally invasive surgical technique and enamel matrix  
33  
34 derivative in intrabony defects. I: Clinical outcomes and morbidity. *J Clin Periodontol*  
35  
36 2007;34:1082–8.  
37  
38  
39 40 Cortellini P and Tonetti MS. Improved wound stability with a modified minimally  
41  
42 invasive surgical technique in the regenerative treatment of isolated interdental intrabony  
43  
44 defects. *J Clin Periodontol* 2009;36:157–63.  
45  
46  
47 48 Takeda K, Mizutani K, Matsuura T, et al. Periodontal regenerative effect of enamel  
49  
50 matrix derivative in diabetes. *PLoS One* 2018;13:e0207201.  
51  
52 53 Sali DD and Pauline George J. Demineralized freeze dried bone allograft with amniotic  
54  
55 membrane in the treatment of periodontal intrabony defects - 12 month randomized  
56  
57 controlled clinical trial. *J Periodontol* 2016;11:1-18.  
58  
59 60 Li F, Yu F, Xu X, et al. Evaluation of Recombinant Human FGF-2 and PDGF-BB in

- 1  
2  
3 Periodontal Regeneration: A Systematic Review and Meta-Analysis. *Sci Rep* 2017;7:65.  
4  
5 21 Nevins ML, Camelo M, Rebaudi A, et al. Three-dimensional micro-computed  
6  
7 tomographic evaluation of periodontal regeneration: a human report of intrabony defects  
8  
9 treated with Bio-Oss collagen. *Int J Periodontics Restorative Dent* 2005;25:365-73.  
10  
11  
12 22 Aimetti M, Romano F, Pigella E, et al. Treatment of wide, shallow, and predominantly  
13  
14 1-wall intrabony defects with a bioabsorbable membrane: A randomized controlled  
15  
16 clinical trial. *J Periodontol* 2005;6:1354-61.  
17  
18  
19 23 Nickles K, Ratka-Krüger P, Neukranz E, et al. Open flap debridement and guided tissue  
20  
21 regeneration after 10 years in infrabony defects. *J Clin Periodontol* 2009;36:976-83.  
22  
23  
24 24 Graziani F, Gennai S, Cei S, et al. Clinical performance of access flap surgery in the  
25  
26 treatment of the intrabony defect. A systematic review and meta-analysis of randomized  
27  
28 clinical trials. *J Clin Periodontol* 2012;39:145-56.  
29  
30  
31  
32 25 Harrel SK and Rees TD. Granulation tissue removal in routine and minimally invasive  
33  
34 procedures. *Compend Contin Educ Dent* 1995;16:960,962,964passim.  
35  
36  
37  
38 26 Cortellini P, Prato GP and Tonetti MS. The Modified Papilla Preservation Technique. A  
39  
40 New Surgical Approach for Interproximal Regenerative Procedures. *J Periodontol*  
41  
42 1995;66:261-6.  
43  
44  
45  
46 27 Cortellini P, Prato GP and Tonetti MS. The Simplified Papilla Preservation Flap. a Novel  
47  
48 Surgical Approach for the Management of Soft Tissues in Regenerative Procedures. *Int J*  
49  
50 *Periodontics Restorative Dent* 1999;19:589-99.  
51  
52  
53  
54 28 Cortellini P and Tonetti MS. A minimally invasive surgical technique with an enamel  
55  
56 matrix derivative in the regenerative treatment of intra-bony defects: a novel approach to  
57  
58 limit morbidity. *J Clin Periodontol* 2007;34:87-93.  
59  
60

- 1  
2  
3 29 Cortellini P, Nieri M, Prato GP, et al. Single minimally invasive surgical technique with  
4  
5 an enamel matrix derivative to treat multiple adjacent intra-bony defects: Clinical  
6  
7 outcomes and patient morbidity. *J Clin Periodontol* 2008;35:605-13.  
8  
9
- 10 30 Aimetti M, Ferrarotti F, Mariani GM, et al. A novel flapless approach versus minimally  
11  
12 invasive surgery in periodontal regeneration with enamel matrix derivative proteins: a  
13  
14 24-month randomized controlled clinical trial. *Clin Oral Investig* 2017;21:327-37.  
15  
16  
17
- 18 31 Liu S, Hu B, Zhang Y, et al. Minimally Invasive Surgery Combined with Regenerative  
19  
20 Biomaterials in Treating Intra-Bony Defects: A Meta-Analysis. *PLoS One*  
21  
22 2016;11:e0147001.  
23  
24  
25
- 26 32 Palachur D, Prabhakara Rao KV, Murthy KR, et al. A comparative evaluation of  
27  
28 bovine-derived xenograft (Bio-Oss Collagen) and type I collagen membrane (Bio-Gide)  
29  
30 with bovine-derived xenograft (Bio-Oss Collagen) and fibrin fibronectin sealing system  
31  
32 (TISSEEL) in the treatment of intrabony defects: A clinico-radiographic study. *J Indian*  
33  
34 *Soc Periodontol* 2014;18:336–43.  
35  
36  
37
- 38 33 Sculean A, Chiantella GC, Windisch P, et al. Healing of intra-bony defects following  
39  
40 treatment with a composite bovine-derived xenograft (Bio-Oss Collagen) in combination  
41  
42 with a collagen membrane (Bio-Gide PERIO). *J Clin Periodontol* 2005;32:720-4.  
43  
44  
45
- 46 34 Tonetti MS, Greenwell H and Kornman KS. Staging and grading of periodontitis:  
47  
48 framework and proposal of a new classification and case definition. *J Clin Periodontol*  
49  
50 2018;45Suppl20:149–61.  
51  
52  
53
- 54 35 De Bruyckere T, Eghbali A, Younes F, et al. A 5-year prospective study on regenerative  
55  
56 periodontal therapy of infrabony defects using minimally invasive surgery and a  
57  
58 collagen-enriched bovine-derived xenograft. *Clin Oral Investig* 2018;22:1235-42.  
59  
60



- 1  
2  
3 36 Cosyn J, Cleymaet R, Hanselaer L, et al. Regenerative periodontal therapy of infrabony  
4 defects using minimally invasive surgery and a collagen-enriched bovine-derived  
5 xenograft: a 1-year prospective study on clinical and aesthetic outcome. *J Clin*  
6  
7  
8  
9  
10 *Periodontol* 2012;39:979–86.  
11  
12  
13 37 Cortellini P and Tonetti MS. Clinical and radiographic outcomes of the modified  
14 minimally invasive surgical technique with and without regenerative materials: a  
15 randomized-controlled trial in intra-bony defects. *J Clin Periodontol* 2011;38:365-73.  
16  
17  
18  
19  
20 38 Mishra A, Avula H, Pathakota KR, et al. Efficacy of modified minimally invasive  
21 surgical technique in the treatment of human intrabony defects with or without use of  
22  
23  
24  
25  
26  
27  
28  
29 39 Tonetti MS, Lang NP, Cortellini P, et al. Enamel matrix proteins in the regenerative  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1. Framework of the trial and CONSORT flow chart

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Framework of the trial and CONSORT flow chart

Periodontitis stage		Stage I	Stage II	Stage III	Stage IV
Severity	Interdental CAL at site of greatest loss	1 to 2 mm	3 to 4 mm	≥5 mm	≥5 mm
	Radiographic bone loss	Coronal third (<15%)	Coronal third (15% to 33%)	Extending to mid-third of root and beyond	Extending to mid-third of root and beyond
	Tooth loss	No tooth loss due to periodontitis		Tooth loss due to periodontitis of ≤4 teeth	Tooth loss due to periodontitis of ≥5 teeth
Complexity	Local	Maximum probing depth ≤4 mm	Maximum probing depth ≤5 mm	In addition to stage II complexity: Probing depth ≥6 mm	In addition to stage III complexity: Need for complex rehabilitation due to:
		Mostly horizontal bone loss	Mostly horizontal bone loss	Vertical bone loss ≥3 mm Furcation involvement Class II or III Moderate ridge defect	Masticatory dysfunction Secondary occlusal trauma (tooth mobility degree ≥2) Severe ridge defect Bite collapse, drifting, flaring Less than 20 remaining teeth (10 opposing pairs)
Extent and distribution	Add to stage as descriptor	For each stage, describe extent as localized (<30% of teeth involved), generalized, or molar/incisor pattern			

The initial stage should be determined using CAL; if not available then RBL should be used. Information on tooth loss that can be attributed primarily to periodontitis – if available – may modify stage definition. This is the case even in the absence of complexity factors. Complexity factors may shift the stage to a higher level, for example furcation II or III would shift to either stage III or IV irrespective of CAL. The distinction between stage III and stage IV is primarily based on complexity factors. For example, a high level of tooth mobility and/or posterior bite collapse would indicate a stage IV diagnosis. For any given case only some, not all, complexity factors may be present, however, in general it only takes one complexity factor to shift the diagnosis to a higher stage. It should be emphasized that these case definitions are guidelines that should be applied using sound clinical judgment to arrive at the most appropriate clinical diagnosis.

For post-treatment patients CAL and RBL are still the primary stage determinants. If a stage-shifting complexity factor(s) is eliminated by treatment, the stage should not retrogress to a lower stage since the original stage complexity factor should always be considered in maintenance phase management.

CAL = clinical attachment loss; RBL = radiographic bone loss.

The stages of periodontitis  
doi: 10.1002/JPER.18-0006

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Page
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	3
Protocol version	3	Date and version identifier	3
Funding	4	Sources and types of financial, material, and other support	15
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1,14
	5b	Name and contact information for the trial sponsor	1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	14
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	
<b>Introduction</b>			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4,5,6
	6b	Explanation for choice of comparators	6
Objectives	7	Specific objectives or hypotheses	6

1				
2	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	7-10
3				
4				
5				
6				
7				
8	<b>Methods: Participants, interventions, and outcomes</b>			
9				
10	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	7
11				
12				
13				
14				
15	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	7,8
16				
17				
18				
19				
20	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	9
21				
22				
23				
24				
25		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	
26				
27				
28				
29				
30		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	10
31				
32				
33				
34				
35		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	11
36				
37				
38	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	6
39				
40				
41				
42				
43				
44				
45				
46	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	7
47				
48				
49				
50				
51				
52	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	11
53				
54				
55				
56	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	7
57				
58				
59				
60	<b>Methods: Assignment of interventions (for controlled trials)</b>			

## Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	8
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	8
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	8
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	8
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	

**Methods: Data collection, management, and analysis**

Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	9
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	9
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	11
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	12
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	

1			
2		20c	Definition of analysis population relating to
3			protocol non-adherence (eg, as randomised analysis), and any
4			statistical methods to handle missing data (eg, multiple imputation)
5			
6			
7			
8			
9			
10			
11			
12			
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			
26			
27			
28			
29			
30			
31			
32			
33			
34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			

**Methods: Monitoring**

Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	11
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	12
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	11
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	

**Ethics and dissemination**

Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	7
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	7
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	7
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	15
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	10

1				
2	Ancillary and	30	Provisions, if any, for ancillary and post-trial care,	
3	post-trial care		and for compensation to those who suffer harm from trial participation	
4				
5	Dissemination	31a	Plans for investigators and sponsor to	13
6	policy		communicate trial results to participants, healthcare professionals,	
7			the public, and other relevant groups (eg, via publication, reporting in	
8			results databases, or other data sharing arrangements), including any	
9			publication restrictions	
10				
11		31b	Authorship eligibility guidelines and any intended	15
12			use of professional writers	
13				
14		31c	Plans, if any, for granting public access	13
15			to the full protocol, participant-level dataset, and statistical code	
16				
17				
18				
19	<b>Appendices</b>			
20				
21	Informed consent	32	Model consent form and other related	
22	materials		documentation given to participants and authorised surrogates	
23				
24	Biological	33	Plans for collection, laboratory evaluation,	
25	specimens		and storage of biological specimens for genetic or molecular analysis	
26			in the current trial and for future use in ancillary studies, if applicable	
27				

---

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.



# BMJ Open

## Modified minimally invasive surgical technique plus Bio-Oss® Collagen for regenerative therapy of isolated interdental intrabony defects: study protocol for a randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-040046.R2
Article Type:	Protocol
Date Submitted by the Author:	09-Sep-2020
Complete List of Authors:	Zhang, Churen; Peking University School of Stomatology, Zhang, Haidong; Peking University School of Stomatology, Department of Periodontology Yue, Zhaoguo; Peking University School of Stomatology, Department of Periodontology Miao, Lili; Peking University School of Stomatology, Department of Periodontology Han, Ye; Peking University School of Stomatology, Department of Periodontology Liu, Kaining; Peking University School of Stomatology, Department of Periodontology Hou, Jianxia; Peking University School of Stomatology, Department of Periodontology
<b>Primary Subject Heading</b>:	Dentistry and oral medicine
Secondary Subject Heading:	Dentistry and oral medicine, Infectious diseases, Surgery
Keywords:	ORAL & MAXILLOFACIAL SURGERY, PLASTIC & RECONSTRUCTIVE SURGERY, Oral & maxillofacial surgery < SURGERY, Clinical trials < THERAPEUTICS

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Modified minimally invasive surgical technique plus Bio-Oss®**  
4  
5 **Collagen for regenerative therapy of isolated interdental**  
6  
7 **intra-bony defects: study protocol for a randomised controlled**  
8  
9 **trial**  
10  
11  
12  
13  
14

15 the corresponding author: Dr. Kai-Ning Liu and Dr. Jian-Xia Hou

16  
17  
18 Address: 22 Zhongguancun South Avenue, Haidian District, Beijing 100081, People's  
19  
20 Republic of China.

21  
22  
23 Email address: [liukainingbjmu@163.com](mailto:liukainingbjmu@163.com) and [jxhou@163.com](mailto:jxhou@163.com)  
24  
25  
26  
27

28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Chu-Ren Zhang<sup>1</sup>, Hai-Dong Zhang<sup>1</sup>, Zhao-Guo Yue<sup>1</sup>, Li-Li Miao<sup>1</sup>, Ye Han<sup>1</sup>, Kai-Ning Liu<sup>1</sup>  
and Jian-Xia Hou<sup>1</sup>

<sup>1</sup>Department of Periodontology, Peking University School and Hospital of Stomatology and  
National Engineering Laboratory for Digital and Material Technology of Stomatology and  
Beijing Key Laboratory of Digital Stomatology, 22 Zhongguancun South Avenue, Haidian  
District, Beijing 100081, People's Republic of China.

the total number of words (except abstract, references, tables and figures): 2571.

## Abstract

### Introduction

Periodontal regeneration surgery has been widely used to deal with intra-bony defects.

Modified minimally invasive surgical technique (M-MIST) is designed to deal with isolated

1  
2 interdental intrabony defects, having achieved satisfactory periodontal regenerative effect.  
3  
4  
5 Bio-Oss® Collagen, as a bioactive material, has been applied to periodontal regeneration. It is  
6  
7 similar to human cancellous bone, with the ability to promote bone formation; further, it has  
8  
9 exceptional plasticity and spatial stability. The combination of different materials and  
10  
11 techniques has become a research hotspot in recent years. By combining the superiority of  
12  
13 regeneration technology and materials, better regenerative effect can be achieved. This study  
14  
15 will search for differences between M-MIST combined with Bio-Oss® Collagen and M-MIST  
16  
17 exclusively in regeneration therapy for intrabony defects.  
18  
19  
20  
21  
22

23 **Methods and Analysis:** The present research is designed as a two group parallel  
24  
25 randomised controlled trial. The total number of patients is 40. The patients will be randomly  
26  
27 assigned to two groups, 20 participants in each group, for further periodontal regenerative  
28  
29 surgery. Test group: M-MIST plus Bio-Oss® Collagen. Control group: M-MIST. After 12  
30  
31 months, the measurement indices will be recorded; these will include clinical attachment gain  
32  
33 and radiographic intrabony defect depth change, as the primary results, and secondary  
34  
35 outcomes of full-mouth plaque scores, probing depth, full-mouth bleeding scores, gingival  
36  
37 recession, mobility, gingival papilla height, and visual analogue scale (VAS). The paired  
38  
39 samples *t*-test will be applied to detect any difference between baseline and one year  
40  
41 registrations. A general linear model will be performed to study the relationship between the  
42  
43 second and the primary outcome.  
44  
45  
46  
47  
48  
49  
50

51 **Ethics and Dissemination:** The present research has received approval from the Ethics  
52  
53 Committee of Peking University School and Hospital of Stomatology  
54  
55 (PKUSSIRB-202053002). Data of the present research will be registered with the  
56  
57 International Clinical Trials Registry Platform. Additionally, we will disseminate the results  
58  
59  
60

1  
2 through scientific dental journals.  
3  
4  
5

6 **Trial registration number:** ChiCTR-2000030851.  
7  
8

9  
10 **Protocol version:** Protocol Version 4, 07.14.2020.  
11  
12

### 13 **Strengths and limitations of this study:** 14

15 This trial is designed as a randomised, examiner-blind clinical trial.  
16

17  
18 The trial will be the first clinical study to compare the periodontal regenerative effect of  
19 M-MIST plus Bio-Oss® Collagen and M-MIST exclusively in isolated interdental intrabony  
20 defects.  
21  
22  
23  
24

25 The follow-up in the trial will last for one year.  
26

27 The outcome of this study will not be applied to patients with systemic disease.  
28  
29

30 **Key words:** Intrabony defect; periodontal regenerative therapy; Bio-Oss® Collagen;  
31 modified minimally invasive surgical technique.  
32  
33  
34  
35  
36  
37  
38  
39  
40

## 41 **INTRODUCTION** 42

43  
44 Periodontal disease is an inflammatory disease, with a high incidence around the teeth. It can  
45 lead to loss of periodontal attachment and alveolar bone, and even to tooth loss.<sup>1,2</sup> Periodontal  
46 disease is caused by multiple factors, of which the initial factor is the interaction between the  
47 biofilm and the immune response.<sup>3</sup> Periodontal pathogens play a key role in the pathogenesis  
48 and development of periodontal and systemic diseases, including diabetes and cardiovascular  
49 diseases, which can influence the development of periodontal disease.<sup>4</sup> It is reported that  
50 periodontitis is one of the most universal diseases around the world.<sup>5</sup> Scaling and root  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 planning (SRP) is the essential therapy for every patient.<sup>6</sup> However, for teeth with deep  
3  
4 periodontal pockets, SRP cannot not achieve a more therapeutic effect than surgery.<sup>7</sup> After  
5  
6 periodontal initial therapy, the residual deep pockets have often been associated with  
7  
8 intrabony defects, identified as a clinical challenge.<sup>8</sup> The intrabony defects may result in  
9  
10 unmanageable inflammation, and ultimately to tooth loss.<sup>9</sup> Therefore, intrabony defects are  
11  
12 generally regarded as surgical indications.<sup>10</sup>  
13  
14  
15  
16  
17

18 Periodontal regeneration surgery has been widely applied to deal with intrabony defects  
19  
20 with the purpose of reforming the periodontal attachment in hopes of saving the involved  
21  
22 teeth.<sup>11-14</sup> In the past 20 years, the development of periodontal regeneration therapy has been  
23  
24 reflected mainly in two aspects. First, surgical design and techniques have been studied,  
25  
26 especially minimally invasive surgery.<sup>15-20</sup> Second, considerable progress has been made in  
27  
28 regenerative materials, such as enamel matrix derivative (EMD),<sup>18</sup> demineralized freeze-dried  
29  
30 bone allograft (DFDBA),<sup>19</sup> recombinant human platelet-derived growth factor BB  
31  
32 (rhPDGF-BB),<sup>20</sup> and spongy bone with collagen (Bio-Oss<sup>®</sup> Collagen).<sup>21</sup> These methods offer  
33  
34 more advantages than simple flap debridement in increasing clinical attachment and  
35  
36 decreasing probing depth of the affected teeth.<sup>22,23</sup> However, common complications, such as  
37  
38 the exposure of barrier membrane and embedded material, have contributed to poor clinical  
39  
40 results of periodontal regeneration surgery.<sup>24</sup>  
41  
42  
43  
44  
45  
46  
47  
48

49 To solve this problem, many periodontal surgical designs and techniques have been  
50  
51 proposed and continually improved on.<sup>25-28</sup> As early as in 1995, Harrel and Ress<sup>25</sup> suggested  
52  
53 applying minimally invasive surgery to periodontal surgical treatment, whose key points were  
54  
55 small incision, small flap, and reduction of damage to soft and hard tissues. In 1995 and  
56  
57 1999, Cortellini<sup>26,27</sup> proposed the papilla preservation techniques to preserve interdental soft  
58  
59  
60

1  
2 tissues as completely as possible and isolate the operative area from the oral environment. On  
3  
4  
5 this basis, to further improve the surgical effect, the concept of minimally invasive surgery  
6  
7  
8 was proposed and gradually improved upon. In 2007, Cortellini and Tonetti<sup>28</sup> proposed a  
9  
10 minimally invasive surgical technique (MIST) to deal with periodontal intrabony defects for  
11  
12 more periodontal tissue regeneration. This technique was designed to reduce surgical trauma,  
13  
14  
15 operative time, and postoperative discomfort.<sup>28</sup> A number of clinical studies<sup>16,29</sup> have  
16  
17  
18 confirmed its effectiveness and advantages of the technique. In 2009, Cortellini and Tonetti<sup>17</sup>  
19  
20 further designed a modified minimally invasive surgical technique (M-MIST). This method  
21  
22  
23 only opened the tiny buccal flap to ensure adequate blood supply, tighter primary wound  
24  
25  
26 closure and lower risk of bacterial infection.

27  
28 In recent years, the combination of different materials and techniques has become a  
29  
30  
31 research hotspot.<sup>30</sup> By combining the advantages of regeneration technology and materials,  
32  
33  
34 better regenerative results can be achieved.<sup>31</sup> M-MIST only opens a small flap on the buccal  
35  
36  
37 side to achieve minimal interdental passage, saving the palatal soft tissue.<sup>17</sup> Bio-Oss<sup>®</sup>  
38  
39 Collagen is similar to human cancellous bone, with the ability to promote bone formation.<sup>32</sup>  
40  
41  
42 Bio-Oss<sup>®</sup> Collagen, with outstanding plasticity and spatial stability,<sup>33</sup> is suitable for the small  
43  
44  
45 field of vision resulting from M-MIST. Therefore, we plan to research the therapeutic effect  
46  
47  
48 of M-MIST combined with Bio-Oss<sup>®</sup> Collagen and the use of M-MIST exclusively for  
49  
50  
51 periodontal tissue regeneration of isolated interdental intrabony defects. The presumption was  
52  
53  
54 raised that combining M-MIST and Bio-Oss<sup>®</sup> Collagen would lead to a better result in  
55  
56  
57 periodontally regenerating intrabony defects than M-MIST alone. The practicability,  
58  
59  
60 applicability and extensibility of the combination will be investigated in the present study.  
The primary outcomes were clinical attachment gain and radiographic bone-filling the

1  
2 intrabony defect, which would be recorded by clinical examination, periapical radiographs  
3  
4 and cone beam computed tomography. The clinical attachment gain and bone filling  
5  
6 represent periodontal tissue regeneration.<sup>17</sup> The secondary outcomes were probing depth,  
7  
8 full-mouth plaque scores, full-mouth bleeding scores, gingival recession, mobility, height of  
9  
10 the gingival papilla, and visual analogue scale (VAS). These indices represent the  
11  
12 inflammatory characteristics of periodontal tissue.<sup>28</sup> The present article describes the design  
13  
14 of the trial.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

## 26 **METHODS AND ANALYSIS**

27  
28 This research is a randomised controlled trial with two parallel groups. It will be carried out  
29  
30 according to the basis of the World Medical Association Declaration of Helsinki. Patients  
31  
32 with stage III or IV periodontitis,<sup>34</sup> (details in the supplemental material 1) needing  
33  
34 periodontal regenerative treatment for isolated intrabony defects are the potential subjects.  
35  
36 This study will be undertaken at Peking University School and Hospital of Stomatology  
37  
38 (Beijing, China). The present research has received approval from the Ethics Committee of  
39  
40 Peking University School and Hospital of Stomatology (PKUSSIRB-202053002), and it is  
41  
42 registered with the International Clinical Trials Registry Platform (ID:  
43  
44 ChiCTR-2000030851). The research framework is shown in Figure 1.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

### 57 **Participant selection**

58  
59 All participants will come from the Periodontology Department at Peking University School  
60



1  
2 and Hospital of Stomatology. At re-evaluation after periodontal initial therapy, if the subject  
3  
4 is found to have isolated intrabony defects, he or she will be informed about the study. The  
5  
6 potential subjects will receive information about the research. The subjects will be  
7  
8 incorporated into this trial only after their signature has been obtained. (informed consent in  
9  
10 the supplemental material 2) The personal information of the consent form will be  
11  
12 confidentially stored in our department.  
13  
14  
15  
16

17  
18 As regards the patient characteristics, the following criteria should be met: (1) age 18 to 75  
19  
20 years; (2) both genders will be considered for selection in the study; (3) patients with stage III  
21  
22 or IV periodontitis at least two months after periodontal initial therapy; (4) good compliance;  
23  
24 (5) good oral hygiene; (6) full-mouth plaque score and full-mouth bleeding score each less  
25  
26 than 30%; (7) systemically healthy. The intrabony defect should be an isolated intrabony  
27  
28 defect of more than 3 mm in depth, combined with more than a 5 mm probing depth and  
29  
30 attachment loss. In addition, the intrabony defect should not exceed in area the lingual surface  
31  
32 area of the root. The morphology of the intrabony defect will be detected during the operation  
33  
34 and finally determined whether the patient would be enrolled in the trial. The associated tooth  
35  
36 should either maintain normal pulp vitality or it should have undergone root canal therapy for  
37  
38 at least six months. The intrabony defect existing around the anterior teeth, the premolars or  
39  
40 at the mesial side of mandibular first molars will be included to avoid the influence of  
41  
42 furcation involvement. Patients with tumours, systemic diseases, or a history of receiving  
43  
44 antibiotics in the past three months will be excluded. The affected teeth with 3° mobility,  
45  
46 furcation involvement, acute periapical inflammation, or root fractures will not be enrolled.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Randomisation and blinding

The random sequence is produced through a random number table and the assignment is saved in a sealed envelope. A research worker unaware of the trial process will be in charge of the randomisation. All subjects will be randomly assigned to two groups. Test group: M-MIST combined with Bio-Oss® Collagen. Control group: M-MIST. All surgical operations will be performed by an experienced therapist in the dark of the assignment. Another two members in the dark of the research plan will respectively take charge of the clinical examination and statistical analysis.

## Interventions

The enrolled participants will receive a periodontal clinical examination. They will have periapical radiographs and cone beam computed tomography taken. The surgical process will be performed as described in the literature<sup>17</sup>: if the width of the top of the gingival papilla is 2 mm or narrower, the simplified papilla preservation flap<sup>27</sup> will be performed; if it is wider than 2 mm, the modified papilla preservation technique<sup>26</sup> will be used. Then the incision will extend along the gingival sulcus on the buccal side of the two adjacent teeth, and a buccal flap will be reflected to expose 1 to 2 mm of buccal bone crest. With miniature blades and mini curettes, the granulation tissue will be curetted and the roots will be carefully planned with curettes. If the depth of the intrabony defect is 3 mm or more and the defect does not contain a lingual intrabony component, the site will be finally enrolled for further examination and statistical analysis. If the intrabony defects do not meet the inclusion criteria, the surgery will be continued, but such defects will not be enrolled for further

1  
2 examination or statistical analysis. After thorough debridement and careful rinsing with saline  
3  
4 solution, the intrabony defect will be filled with Bio-Oss® Collagen, level with the buccal  
5  
6 bone crest, in the test group. In the control group, intrabony defects will not be treated with  
7  
8 any other materials. Finally, a vertical mattress suture will be performed to close the wound.  
9  
10  
11 Periapical films of the defect associated site will be taken immediately after the surgery. If  
12  
13 the tooth appears to have 2 to 3° mobility after the surgery, the tooth will be promptly  
14  
15 splinted. The patients will be required to rinse with a 0.2% chlorhexidine solution for one  
16  
17 week, and the suture will be removed one week after surgery.  
18  
19  
20  
21  
22

23 The surgeries will be performed at the Periodontology Department, Peking University  
24  
25 School and Hospital of Stomatology. An experienced periodontist with the help of an  
26  
27 operating microscope will perform all operations.  
28  
29  
30  
31  
32  
33  
34  
35

### 36 **Examination**

37  
38 At baseline, all the enrolled subjects will receive a periodontal examination by two  
39  
40 experienced research professionals who have passed the inter-examiner agreement exam.  
41  
42 Relative periodontal indexes will include full-mouth plaque score,<sup>28</sup> clinical attachment loss  
43  
44 of the involved teeth,<sup>29</sup> full-mouth bleeding score,<sup>28</sup> gingival recession of the involved teeth,<sup>14</sup>  
45  
46 mobility of the involved teeth,<sup>28</sup> probing depth of the involved teeth,<sup>29</sup> height of the gingival  
47  
48 papilla,<sup>29</sup> periapical films and cone beam computed tomography of the interdental site.<sup>28</sup>  
49  
50 During the surgery, the defect anatomy, including the depth and number of walls of the  
51  
52 intrabony defects, will be examined by the operator. The patients will receive a phone-call for  
53  
54 re-examinations at 1 week and 1, 3, 6, 9, and 12 months post-surgery. At 1, 3, 6, 9, and 12  
55  
56  
57  
58  
59  
60

1  
2 months post-surgery, a full-mouth plaque score and gingival papilla height will be recorded  
3  
4  
5 by the same calibrated examiners. At 12 months post-treatment, a full-mouth plaque score,  
6  
7 clinical attachment gain of the involved teeth, gingival recession, mobility, full-mouth  
8  
9 bleeding score, gingival papilla height, probing depth of the involved teeth will be examined  
10  
11 by the same examiners. Periapical films and cone beam computed tomography of the defect  
12  
13 associated site will be taken 6 and 12 months post-surgery. In addition, subjects will finish a  
14  
15 VAS to evaluate the discomfort after 1 week of treatment. During the follow-up,  
16  
17 complications will be recorded and treated once they happen. At re-evaluation, if the oral  
18  
19 hygiene is deficient, we will clean the teeth by supragingival scaling and reinforcing oral  
20  
21 hygiene instruction. All the data will be recorded in the periodontal examination charts and  
22  
23 be registered and stored in the computer. There is no data monitoring committee in our  
24  
25 hospital, so to ensure the correction and integrity of data, two different researchers will take  
26  
27 charge of the management and storage of data.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

### 42 **Sample size**

43  
44 The needed number of participants was calculated according to the formula:

$$45 \quad n1 = n2 = 2 \left[ \frac{\sigma(Z_{\alpha/2} + Z_{\beta})}{\delta} \right]^2$$

46  
47  
48  
49 On the basis of previous literature,<sup>17,35</sup> the difference of clinical attachment gain using  
50  
51 Bio-Oss® Collagen or not ( $\delta$ ) was about 1.5 mm and the standard deviation ( $\sigma$ ) was about 1.4  
52  
53 mm. The power of test ( $\beta$ ) is set as 10% and the inspection level ( $\alpha$ ) is set as 0.05. After  
54  
55 calculation, 18 subjects will be needed for each group. Suppose that the rate of subjects lost  
56  
57 during follow up is around 10%, 20 subjects will be needed for each group. Ultimately, at  
58  
59  
60

1  
2  
3 least 40 subjects will be needed in all.  
4  
5  
6  
7  
8  
9

### 10 **Statistical analysis**

11  
12 One patient will be identified as a data unit. If two or more intrabony defects go through the  
13 surgery in one patient, only one defect nearest to the midline will be enrolled.<sup>36</sup> The paired  
14 samples *t*-test will be applied to detect any difference between baseline and one year  
15 registrations. A general linear model will be performed to study the relationship between the  
16 defect depth, number of bony walls, full-mouth plaque score and full-mouth bleeding score  
17 with clinical attachment gain, probing depth reduction and radiographic intrabony defect  
18 depth change. The level of statistically significant difference will be set at 0.05. Statistical  
19 analysis will be done using SPSS version 26.0 software.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

### 40 **Withdrawal**

41 Participants will be told that they can quit the research at any time. The withdrawal will not  
42 influence their receiving help from departmental periodontists in the future.  
43  
44  
45  
46  
47  
48  
49  
50  
51

### 52 **Dissemination of data**

53  
54 Data from the present research will be registered with the International Clinical Trials  
55 Registry Platform. Additionally, we will disseminate the results through scientific dental  
56 journals.  
57  
58  
59  
60

## DISCUSSION

For an isolated intrabony defect, M-MIST could be an effective treatment method, with an average clinical attachment gain of 4.8 mm at 1 year post-surgery.<sup>17</sup> It allows access to the root surface with only the buccal flap opening, which is minimally invasive and further enhances wound stability. However, when bioactive materials, such as EMD and rhPDGF-BB, were used combined with M-MIST, periodontal regenerative effects were not better.<sup>37,38</sup> EMD might not be an ideal bioactive material in dealing with wide defects.<sup>39</sup> Bio-Oss<sup>®</sup> Collagen is a bovine derived xenograft containing profuse collagen that can fit into different types of defects.<sup>33</sup> The present research is designed to study the effectiveness and potential applicability of M-MIST combined with Bio-Oss<sup>®</sup> Collagen for tissue regeneration of periodontal intrabony defects. If the results of M-MIST combined with Bio-Oss<sup>®</sup> Collagen turned out to be better than those of M-MIST alone in terms of radiographic and clinical defect improvement, Bio-Oss<sup>®</sup> Collagen might be considered as a combined application with M-MIST for periodontal tissue regeneration of intrabony defects.

### **Ethics and Dissemination:**

The present research has received approval from the Ethics Committee of Peking University School and Hospital of Stomatology (PKUSSIRB-202053002). The subjects will be incorporated into this trial only after their signature has been obtained. The study will be performed according to the 2013 revision of the Helsinki Declaration of 1975. Personal

1  
2 information of all subjects will be stored in the Department of Periodontology at Peking  
3  
4 University School and Hospital of Stomatology. Data of the present research will be  
5  
6 registered with the International Clinical Trials Registry Platform. Additionally, we will  
7  
8 disseminate the results through scientific journals.  
9  
10  
11  
12  
13  
14

## 15 **Trial status**

16  
17 The trial protocol received ethics approval in March 2020 and was registered at the  
18  
19 International Clinical Trials Registry Platform (ID: ChiCTR-2000030851) on March 15,  
20  
21 2020. The trial will begin after the COVID-19 pandemic has been controlled; it is scheduled  
22  
23 to be completed in October, 2021.  
24  
25  
26  
27  
28  
29  
30  
31  
32

## 33 **Acknowledgements**

34 Not applicable  
35  
36  
37  
38  
39  
40  
41  
42  
43

## 44 **Contributors**

45  
46 H-DZ, K-NL, C-RZ and J-XH proposed the concept of this work. C-RZ, K-NL and J-XH  
47  
48 designed the trial. C-RZ and H-DZ drafted the document. Z-GY, L-LM and YH revised the  
49  
50 part on randomisation and calculation of the sample size. K-NL and J-XH reviewed and  
51  
52 finalised the manuscript. All authors agreed to the final version.  
53  
54  
55  
56  
57  
58  
59  
60

## **Funding**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

## **Competing interests**

The authors declare that there is no conflict of interest

## **Patient and public involvement**

Neither patients nor the public were associated with either the design or dissemination scheme of this work.

## **Patient consent for publication**

Not required.

## **ORCID ID**

Chu-Ren Zhang [http:// orcid. org/ 0000-0001-9070-7138](http://orcid.org/0000-0001-9070-7138)

## **REFERENCES**



- 1  
2  
3 1 Tonetti MS, Eickholz P, Loos BG, et al. Principles in prevention of periodontal diseases:  
4  
5 consensus report of group 1 of the 11th European Workshop on Periodontology on  
6  
7 effective prevention of periodontal and peri-implant diseases. *J Clin Periodontol*  
8  
9 2015;42Suppl16:5-11.  
10  
11
- 12  
13 2 Ramseier CA, Anerud A, Dulac M, et al. Natural history of periodontitis: disease  
14  
15 progression and tooth loss over 40 years. *J Clin Periodontol* 2017;44:1182-91.  
16  
17
- 18  
19 3 Meyle J, Chapple I. Molecular aspects of the pathogenesis of periodontitis. *Periodontol*  
20  
21 *2000* 2015;69:7-17.  
22
- 23  
24 4 Hasturk H, Kantarci A. Activation and resolution of periodontal inflammation and its  
25  
26 systemic impact. *Periodontol 2000* 2015;69:255–73.  
27
- 28  
29 5 GBD 2015 SDG Collaborators. Measuring the health-related Sustainable Development  
30  
31 Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study  
32  
33 2015. *Lancet* 2016;388:1813–50.  
34  
35
- 36  
37 6 Berezow AB and Darveau RP. Microbial shift and periodontitis. *Periodontol 2000*  
38  
39 2011;55:36-47.  
40
- 41  
42 7 Serino G, Rosling B, Ramberg P, et al. Initial outcome and long-term effect of surgical  
43  
44 and non-surgical treatment of advanced periodontal disease. *J Clin Periodontol*  
45  
46 2001;28:910–6.  
47  
48
- 49  
50 8 Cortellini P and Tonetti MS. Clinical concepts for regenerative therapy in intrabony  
51  
52 defects. *Periodontol 2000* 2015;68:282-307.  
53
- 54  
55 9 Matuliene G, Pjetursson BE, Salvi GE, et al. Influence of residual pockets on progression  
56  
57 of periodontitis and tooth loss: results after 11 years of maintenance. *J Clin Periodontol*  
58  
59 2008;35:685–95.  
60

- 1  
2  
3 10 Reynolds MA, Kao RT, Camargo PM, et al. Periodontal regeneration-intrabony defects:  
4  
5 a consensus report from the AAP Regeneration Workshop. *J Periodontol*  
6  
7 2015;86Suppl2:105-7.  
8  
9  
10 11 Sanz M, Tonetti MS, Zabalegui I, et al. Treatment of intrabony defects with enamel  
12  
13 matrix proteins or barrier membranes: Results from a multicenter practice-based clinical  
14  
15 trial. *J Periodontol* 2004;75:726–33.  
16  
17  
18 12 Sculean A, Kiss A, Miliauskaite A, et al. Ten-year results following treatment of  
19  
20 intrabony defects with enamel matrix proteins and guided tissue regeneration. *J Clin*  
21  
22 *Periodontol* 2008;35:817–24.  
23  
24  
25 13 Paolantonio M, Femminella B, Coppolino E, et al. Autogenous periosteal barrier  
26  
27 membranes and bone grafts in the treatment of periodontal intrabony defects of  
28  
29 single-rooted teeth: A 12-month reentry randomized controlled clinical trial. *J*  
30  
31 *Periodontol* 2010;81:1587–95.  
32  
33  
34  
35 14 Cortellini P, Buti J, Pini Prato G, et al. Periodontal regeneration compared with access  
36  
37 flap surgery in human intra-bony defects 20-year follow-up of a randomized clinical  
38  
39 trial: tooth retention, periodontitis recurrence and costs. *J Clin Periodontol*  
40  
41 2017;44:59-66.  
42  
43  
44  
45 15 Wachtel H, Schenk G, Böhm S, et al. Microsurgical access flap and enamel matrix  
46  
47 derivative for the treatment of periodontal intrabony defects: A controlled clinical study.  
48  
49 *J Clin Periodontol* 2003;30:496–504.  
50  
51  
52  
53 16 Cortellini P and Tonetti MS. Minimally invasive surgical technique and enamel matrix  
54  
55 derivative in intrabony defects. I: Clinical outcomes and morbidity. *J Clin Periodontol*  
56  
57 2007;34:1082–8.  
58  
59  
60

- 1  
2  
3 17 Cortellini P and Tonetti MS. Improved wound stability with a modified minimally  
4  
5 invasive surgical technique in the regenerative treatment of isolated interdental intrabony  
6  
7 defects. *J Clin Periodontol* 2009;36:157–63.  
8  
9
- 10 18 Takeda K, Mizutani K, Matsuura T, et al. Periodontal regenerative effect of enamel  
11  
12 matrix derivative in diabetes. *PLoS One* 2018;13:e0207201.  
13  
14
- 15 19 Sali DD and Pauline George J. Demineralized freeze dried bone allograft with amniotic  
16  
17 membrane in the treatment of periodontal intrabony defects - 12 month randomized  
18  
19 controlled clinical trial. *J Periodontol* 2016;11:1-18.  
20  
21
- 22 20 Li F, Yu F, Xu X, et al. Evaluation of Recombinant Human FGF-2 and PDGF-BB in  
23  
24 Periodontal Regeneration: A Systematic Review and Meta-Analysis. *Sci Rep* 2017;7:65.  
25  
26
- 27 21 Nevins ML, Camelo M, Rebaudi A, et al. Three-dimensional micro-computed  
28  
29 tomographic evaluation of periodontal regeneration: a human report of intrabony defects  
30  
31 treated with Bio-Oss collagen. *Int J Periodontics Restorative Dent* 2005;25:365-73.  
32  
33
- 34 22 Aimetti M, Romano F, Pigella E, et al. Treatment of wide, shallow, and predominantly  
35  
36 1-wall intrabony defects with a bioabsorbable membrane: A randomized controlled  
37  
38 clinical trial. *J Periodontol* 2005;6:1354–61.  
39  
40
- 41 23 Nickles K, Ratka-Krüger P, Neukranz E, et al. Open flap debridement and guided tissue  
42  
43 regeneration after 10 years in infrabony defects. *J Clin Periodontol* 2009;36:976–83.  
44  
45
- 46 24 Graziani F, Gennai S, Cei S, et al. Clinical performance of access flap surgery in the  
47  
48 treatment of the intrabony defect. A systematic review and meta-analysis of randomized  
49  
50 clinical trials. *J Clin Periodontol* 2012;39:145–56.  
51  
52
- 53 25 Harrel SK and Rees TD. Granulation tissue removal in routine and minimally invasive  
54  
55 procedures. *Compend Contin Educ Dent* 1995;16:960,962,964passim.  
56  
57  
58  
59  
60

- 1  
2  
3 26 Cortellini P, Prato GP and Tonetti MS. The Modified Papilla Preservation Technique. A  
4  
5 New Surgical Approach for Interproximal Regenerative Procedures. *J Periodontol*  
6  
7 1995;66:261-6.  
8  
9  
10 27 Cortellini P, Prato GP and Tonetti MS. The Simplified Papilla Preservation Flap. a Novel  
11  
12 Surgical Approach for the Management of Soft Tissues in Regenerative Procedures. *Int J*  
13  
14 *Periodontics Restorative Dent* 1999;19:589-99.  
15  
16  
17 28 Cortellini P and Tonetti MS. A minimally invasive surgical technique with an enamel  
18  
19 matrix derivative in the regenerative treatment of intra-bony defects: a novel approach to  
20  
21 limit morbidity. *J Clin Periodontol* 2007;34:87-93.  
22  
23  
24 29 Cortellini P, Nieri M, Prato GP, et al. Single minimally invasive surgical technique with  
25  
26 an enamel matrix derivative to treat multiple adjacent intra-bony defects: Clinical  
27  
28 outcomes and patient morbidity. *J Clin Periodontol* 2008;35:605-13.  
29  
30  
31 30 Aimetti M, Ferrarotti F, Mariani GM, et al. A novel flapless approach versus minimally  
32  
33 invasive surgery in periodontal regeneration with enamel matrix derivative proteins: a  
34  
35 24-month randomized controlled clinical trial. *Clin Oral Investig* 2017;21:327-37.  
36  
37  
38 31 Liu S, Hu B, Zhang Y, et al. Minimally Invasive Surgery Combined with Regenerative  
39  
40 Biomaterials in Treating Intra-Bony Defects: A Meta-Analysis. *PLoS One*  
41  
42 2016;11:e0147001.  
43  
44  
45 32 Palachur D, Prabhakara Rao KV, Murthy KR, et al. A comparative evaluation of  
46  
47 bovine-derived xenograft (Bio-Oss Collagen) and type I collagen membrane (Bio-Gide)  
48  
49 with bovine-derived xenograft (Bio-Oss Collagen) and fibrin fibronectin sealing system  
50  
51 (TISSEEL) in the treatment of intrabony defects: A clinico-radiographic study. *J Indian*  
52  
53 *Soc Periodontol* 2014;18:336-43.  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 33 Sculean A, Chiantella GC, Windisch P, et al. Healing of intra-bony defects following  
4  
5 treatment with a composite bovine-derived xenograft (Bio-Oss Collagen) in combination  
6  
7 with a collagen membrane (Bio-Gide PERIO). *J Clin Periodontol* 2005;32:720-4.  
8  
9
- 10 34 Tonetti MS, Greenwell H and Kornman KS. Staging and grading of periodontitis:  
11  
12 framework and proposal of a new classification and case definition. *J Clin Periodontol*  
13  
14 2018;45Suppl20:149–61.  
15  
16
- 17 35 De Bruyckere T, Eghbali A, Younes F, et al. A 5-year prospective study on regenerative  
18  
19 periodontal therapy of infrabony defects using minimally invasive surgery and a  
20  
21 collagen-enriched bovine-derived xenograft. *Clin Oral Investig* 2018;22:1235-42.  
22  
23  
24
- 25 36 Cosyn J, Cleymaet R, Hanselaer L, et al. Regenerative periodontal therapy of infrabony  
26  
27 defects using minimally invasive surgery and a collagen-enriched bovine-derived  
28  
29 xenograft: a 1-year prospective study on clinical and aesthetic outcome. *J Clin*  
30  
31 *Periodontol* 2012;39:979–86.  
32  
33  
34
- 35 37 Cortellini P and Tonetti MS. Clinical and radiographic outcomes of the modified  
36  
37 minimally invasive surgical technique with and without regenerative materials: a  
38  
39 randomized-controlled trial in intra-bony defects. *J Clin Periodontol* 2011;38:365-73.  
40  
41  
42
- 43 38 Mishra A, Avula H, Pathakota KR, et al. Efficacy of modified minimally invasive  
44  
45 surgical technique in the treatment of human intrabony defects with or without use of  
46  
47 rhPDGF-BB gel: a randomized controlled trial. *J Clin Periodontol* 2013;40:172-9.  
48  
49  
50
- 51 39 Tonetti MS, Lang NP, Cortellini P, et al. Enamel matrix proteins in the regenerative  
52  
53 therapy of deep intrabony defects. *J Clin Periodontol* 2002;29:317–25.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Figure 1. Framework of the trial and CONSORT flow chart




Figure 1. Framework of the trial and CONSORT flow chart

**TABLE 3** Periodontitis stage – PIM Open text and appendix A (in online *Journal of Periodontology*) for explanation

Periodontitis stage		Stage I	Stage II	Stage III	Stage IV
Severity	Interdental CAL at site of greatest loss	1 to 2 mm	3 to 4 mm	≥5 mm	≥5 mm
	Radiographic bone loss	Coronal third (<15%)	Coronal third (15% to 33%)	Extending to mid-third of root and beyond	Extending to mid-third of root and beyond
	Tooth loss	No tooth loss due to periodontitis		Tooth loss due to periodontitis of ≤4 teeth	Tooth loss due to periodontitis of ≥5 teeth
Complexity	Local	Maximum probing depth ≤4 mm	Maximum probing depth ≤5 mm	In addition to stage II complexity: Probing depth ≥6 mm	In addition to stage III complexity: Need for complex rehabilitation due to:
		Mostly horizontal bone loss	Mostly horizontal bone loss	Vertical bone loss ≥3 mm Furcation involvement Class II or III Moderate ridge defect	Masticatory dysfunction Secondary occlusal trauma (tooth mobility degree ≥2) Severe ridge defect Bite collapse, drifting, flaring Less than 20 remaining teeth (10 opposing pairs)
Extent and distribution	Add to stage as descriptor	For each stage, describe extent as localized (<30% of teeth involved), generalized, or molar/incisor pattern			

The initial stage should be determined using CAL; if not available then RBL should be used. Information on tooth loss that can be attributed primarily to periodontitis – if available – may modify stage definition. This is the case even in the absence of complexity factors. Complexity factors may shift the stage to a higher level, for example furcation II or III would shift to either stage III or IV irrespective of CAL. The distinction between stage III and stage IV is primarily based on complexity factors. For example, a high level of tooth mobility and/or posterior bite collapse would indicate a stage IV diagnosis. For any given case only some, not all, complexity factors may be present, however, in general it only takes one complexity factor to shift the diagnosis to a higher stage. It should be emphasized that these case definitions are guidelines that should be applied using sound clinical judgment to arrive at the most appropriate clinical diagnosis.

For post-treatment patients CAL and RBL are still the primary stage determinants. If a stage-shifting complexity factor(s) is eliminated by treatment, the stage should not retrogress to a lower stage since the original stage complexity factor should always be considered in maintenance phase management.

CAL = clinical attachment loss; RBL = radiographic bone loss.

The stages of periodontitis  
doi: 10.1002/JPER.18-0006



## Informed consent

### Dear patients:

You will be invited to participate in a study led by Dr. Kaining Liu in the Department of Periodontology at Peking University School and Hospital of Stomatology. This study will observe the regenerative effect of modified minimally invasive surgical technique (M-MIST) combined with Bio-Oss® Collagen for isolated interdental intrabony defects. The study will last 12 months. The total number of patients is 40. Since you meet the inclusion criteria, you are invited to join this study.

This informed consent form provides you with important information to help you decide whether to participate in this study. Your participation in this study is voluntary. This study has been reviewed and approved by Ethics Committee of Peking University School and Hospital of Stomatology. If you agree to join this research, please read the following instructions:

Please read it carefully. If you have any questions, please consult the researcher in charge of the study.

### Background:

A modified minimally invasive surgical technique (M-MIST) was proposed to be used in the periodontal regeneration therapy for isolated interdental intrabony defects in 2009. It has been used for more than 10 years, and there have been more than 100 cases reported in the literatures. This technique only elevates the buccal flap to ensure adequate blood supply, tighter primary wound closure and lower risk of bacterial infection. In addition, Bio-Oss® Collagen is similar to human cancellous bone, with the ability to promote bone formation. Bio-Oss® Collagen, with outstanding plasticity and spatial stability, is suitable for the small field of vision resulting from

1  
2  
3  
4 M-MIST.

5  
6 Recently, the combination of different materials and techniques has become a research hotspot.  
7  
8  
9 By combining the advantages of regeneration technology and materials, better regenerative results  
10  
11 can be achieved. Therefore, we plan to research the therapeutic effect of M-MIST combined with  
12  
13 Bio-Oss® Collagen and the use of M-MIST exclusively for periodontal tissue regeneration of  
14  
15 isolated interdental intrabony defects.  
16  
17

18  
19 **Research plan:**

20  
21 You will be randomly assigned to one of the two groups. Test group: M-MIST combined with  
22  
23 Bio-Oss® Collagen. Control group: M-MIST. All surgical operations will be performed by an  
24  
25 experienced therapist. Before surgery, you will receive a periodontal clinical examination and  
26  
27 have periapical radiographs and cone beam computed tomography taken. You will receive a  
28  
29 phone-call for re-examinations at 1 week and 1, 3, 6, 9, and 12 months post-surgery. Periapical  
30  
31 films and cone beam computed tomography of the defect associated site will be taken 6 and 12  
32  
33 months post-surgery. In addition, you will finish a VAS to evaluate the discomfort after 1 week of  
34  
35 treatment.  
36  
37  
38  
39  
40  
41

42  
43 All patients are randomly grouped according to the random sequence, and you will have an  
44  
45 equal chance of being assigned to each group. Neither you nor the therapist can choose your  
46  
47 treatment group.  
48  
49

50  
51 The following criteria should be met:

- 52  
53 (1) age 18 to 75 years;  
54  
55 (2) both genders will be considered for selection in the study;  
56  
57  
58 (3) patients with stage III or IV periodontitis at least two months after periodontal initial  
59  
60

1  
2  
3  
4 therapy;

5  
6 (4) good compliance;

7  
8 (5) good oral hygiene;

9  
10 (6) full-mouth plaque score and full-mouth bleeding score each less than 30%;

11  
12 (7) systemically healthy.

13  
14  
15  
16  
17 **Your responsibilities:**

18  
19 The study will last for 12 months. You will receive a phone-call for re-examinations at 1 week  
20  
21 and 1, 3, 6, 9, and 12 months post-surgery.

22  
23 During the follow-up period, you also need to maintain good oral hygiene. The above items will  
24  
25 not increase the number and time of your visits. Periodontal treatment has the characteristics of  
26  
27 lasting life, so after the study, periodontal maintenance treatment will be offered for you.  
28  
29

30  
31  
32 **The impact of participating in the study on your life:**

33  
34 You may feel that these visits and examinations are inconvenient. In addition, some  
35  
36 examinations may make you feel uncomfortable. If you have any questions about the  
37  
38 examinations and procedures in the study, you can consult the researchers.  
39  
40

41  
42 During the entire study period, you can no longer participate in any other clinical trials related  
43  
44 to drugs or medical devices.  
45  
46

47  
48 **Risks and adverse effects of participating in this study:**

49  
50 During the study, you may experience common discomfort after periodontal surgery (see the  
51  
52 informed consent form for periodontal surgery for details). We will monitor all patients in the  
53  
54 study for any adverse reactions. If you have any adverse reactions during the research process,  
55  
56 please call your doctor for consultation in time, and we will perform treatment accordingly.  
57  
58  
59  
60

1  
2  
3  
4 You need to tell your family or friends close to you that you are participating in a clinical study  
5  
6 and they can pay attention to the events described above. If they have questions about your  
7  
8 participation in the study, you can tell them how to contact your doctor.  
9  
10

11 **Are there any other treatment options:**

12  
13  
14 Although there is already evidence that the M-MIST is effective for treating isolated interdental  
15  
16 intrabony defects, it is not guaranteed to be effective for you. The M-MIST + Bio-Oss® Collagen  
17  
18 used in this study is not the only way to treat isolated interdental intrabony defects. You can also  
19  
20 ask your doctor about other treatments you might get.  
21  
22  
23

24 **Expenses, compensation and remuneration for participating in this research association:**

25  
26  
27 There is no compensation for this study. All examination and treatment costs are borne by the  
28  
29 yourself.  
30  
31

32 We will arrange supportive periodontal therapy for you, as well as oral hygiene guidance and  
33  
34 related consultations.  
35  
36

37 **Confidentiality of your personal information:**

38  
39  
40 If you decide to participate in this study, your participation in the experiment and your personal  
41  
42 information in the experiment are confidential. Your name, ID number, address, phone number, or  
43  
44 any information that can directly identify you in the research records will not be leaked outside the  
45  
46 Peking University School and Hospital of Stomatology. We will use a unique number to represent  
47  
48 your research information that is sent outside the Peking University School and Hospital of  
49  
50 Stomatology. The coded information will be properly stored in Peking University School and  
51  
52 Hospital of Stomatology.  
53  
54  
55  
56  
57

58 At any time during the study, you can request access to your personal information (such as your  
59  
60

1  
2  
3  
4 name and address), and modify this information if necessary.  
5

6  
7 **withdraw**

8  
9 You can quit the research at any time. The withdrawal will not influence you further treatment  
10  
11 in the Department of Periodontology.  
12

13  
14 **Contact information**

15  
16 If you have any questions related to this research, or if you have any discomfort or injury during  
17  
18 the research process, or have questions about the rights of participants in this research, you can  
19  
20 contact Dr. Haidong Zhang, Office Tel: 010- 82195367; mobile phone: 13426305500. Or contact  
21  
22 the Ethics Committee of Peking University School and Hospital of Stomatology, Tel: 010-  
23  
24 82195759, Email: [keyanchuethics@163.com](mailto:keyanchuethics@163.com)  
25  
26  
27  
28  
29

30 **Competing interests**

31  
32 None  
33  
34  
35  
36  
37  
38  
39

40 **Subject's agreement statement:**

41  
42 I have read the above introduction about this research and fully understand the possible risks  
43  
44 and benefits of participating in this research. I have voluntarily agreed to participate in the clinical  
45  
46 research described in this article.  
47  
48  
49

50 Name of the subject: \_\_\_\_\_

51  
52  
53 Signature date: \_\_\_\_\_ Phone number: \_\_\_\_\_  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Researcher's statement:**

I confirm that I have explained the details of this study to the patient, especially the possible risks and benefits of participating in this study.

Name of the researcher: \_\_\_\_\_

Signature date: \_\_\_\_\_ Phone number: \_\_\_\_\_

For peer review only



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Page
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	3
Protocol version	3	Date and version identifier	3
Funding	4	Sources and types of financial, material, and other support	15
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1,14
	5b	Name and contact information for the trial sponsor	1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	14
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	
<b>Introduction</b>			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4,5,6
	6b	Explanation for choice of comparators	6
Objectives	7	Specific objectives or hypotheses	6

1				
2	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	7-10
3				
4				
5				
6				
7				
8	<b>Methods: Participants, interventions, and outcomes</b>			
9				
10	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	7
11				
12				
13				
14				
15	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	7,8
16				
17				
18				
19				
20	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	9
21				
22				
23				
24				
25		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	
26				
27				
28				
29				
30		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	10
31				
32				
33				
34				
35		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	11
36				
37				
38	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	6
39				
40				
41				
42				
43				
44				
45				
46	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	7
47				
48				
49				
50				
51				
52	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	11
53				
54				
55				
56	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	7
57				
58				
59				
60	<b>Methods: Assignment of interventions (for controlled trials)</b>			



## Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	8
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	8
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	8
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	8
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	

**Methods: Data collection, management, and analysis**

Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	9
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	9
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	11
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	12
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

20c Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)

### Methods: Monitoring

Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	11
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	12
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	11
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	

### Ethics and dissemination

Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	7
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	7
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	7
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	15
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	10

1				
2	Ancillary and	30	Provisions, if any, for ancillary and post-trial care,	
3	post-trial care		and for compensation to those who suffer harm from trial participation	
4				
5	Dissemination	31a	Plans for investigators and sponsor to	13
6	policy		communicate trial results to participants, healthcare professionals,	
7			the public, and other relevant groups (eg, via publication, reporting in	
8			results databases, or other data sharing arrangements), including any	
9			publication restrictions	
10				
11		31b	Authorship eligibility guidelines and any intended	15
12			use of professional writers	
13				
14		31c	Plans, if any, for granting public access	13
15			to the full protocol, participant-level dataset, and statistical code	
16				
17				
18				
19	<b>Appendices</b>			
20				
21	Informed consent	32	Model consent form and other related	sup 2
22	materials		documentation given to participants and authorised surrogates	
23				
24	Biological	33	Plans for collection, laboratory evaluation,	
25	specimens		and storage of biological specimens for genetic or molecular analysis	
26			in the current trial and for future use in ancillary studies, if applicable	
27				

---

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.